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ABSTRACT 
 
     The yeast Saccharomyces cerevisiae has long been used to model complex cellular 
processes. As a eukaryote, much of its fundamental biology is conserved with higher 
organisms. As a single-celled, genetically tractable organism, it can easily be utilized for 
both high-throughput screening and hypothesis-driven analysis. Therefore, many groups 
use yeast to model disease-related proteins. 
     One such model utilizes heterologous expression of α-synuclein (α-syn), a protein 
implicated in the progression of Parkinson’s disease and other synucleinopathies. α-Syn 
expression in yeast is associated with many phenotypes that are recapitulated in higher 
organisms. Here, I used yeast to characterize two naturally occurring splice isoforms of α-
syn, α-synΔ4 and α-synΔ6. Levels of these isoforms vary between synucleinopathies but 
little is known about their biology. I found that these splice isoforms display different 
localization patterns than full-length α-syn (α-synFL) and are less toxic in yeast. However, 
when expressed at a high level, both splice isoforms can exert toxicity and affect similar 
processes to α-synFL. Interestingly, the splice isoforms show differential responses to 
perturbations in sterol homeostasis. Studies concerning the relationship between sterol 
levels and synucleinopathy progression have been contradictory. Our findings reveal that 
α-synΔ4 is less sensitive to changes in sterol levels than α-synFL and α-synΔ6, suggesting 
that change in α-syn splice isoforms levels is a potential mechanism for these conflicting 
results.  
     I also describe an attempt to model torsinA pathobiology in yeast. Mutations in torsinA 
cause early onset torsion dystonia, a devastating motor disorder. This protein has been 
described to function in regulating endoplasmic reticulum (ER) stress through the unfolded 
protein response (UPR). While I was unable to recapitulate a role for torsinA in the UPR in 
yeast, this model can serve as a platform for discovery of torsinA cofactors that enable it to 
act in this capacity, especially as more is uncovered concerning torsinA’s role in the UPR.  
     This thesis highlights both the strengths and limitations of modeling disease proteins in 
yeast.  More specifically, my success with α-syn splice isoforms may provide insight into 
synucleinopathy etiology, while my inability to model torsinA-induced toxicity can inform 
subsequent attempts to study disease related proteins in yeast.  
 
Thesis supervisor: Susan Lindquist 
Title: Professor of Biology 
 
  
4 
 
  
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For my parents, whose endless support has enabled all I have achieved  
6 
 
 
7 
 
Acknowledgements  
      
     The work presented in this manuscript would not have been possible without the help and 
support of a wide variety of individuals. First and foremost, I must thank my thesis advisor, 
Susan Lindquist. Her tremendous support and understanding, both academically and 
personally, is more than I could have ever hoped for in an advisor. I will always appreciate the 
amount of scientific freedom she provided me, even as a starting graduate student, which, 
combined with her well-directed guidance, allowed me to make my own way through these 
projects. From her, I have learned so much about the entirety of the scientific process, which has 
greatly improved my abilities as a scientist.  
 
     I am also grateful to my thesis committee. Angelika Amon and Troy Littleton served on my 
committee from the beginning and provided much guidance concerning the direction of my 
projects, as well as my career. I would also like to thank David Housman and Mel Feany for 
joining my thesis defense committee – I look forward to hearing their comments on this work.  
 
     Sue has also supported my scientific career by hiring some of the most dedicated and 
thoughtful people I could have ever hoped to be fortunate enough to work with. The members 
of the Lindquist lab truly make me look forward to coming to lab every day, even when none of 
my experiments are working. While I cannot thank each of you individually here, I have enjoyed 
working with each and every one of you.  
 
     Brooke Bevis, who is the lab manager of the Lindquist lab, has been my bay-mate for the 
entirety of my graduate career. She has guided me every step of graduate school and served not 
just a bay-mate, but also as a sounding board for all types of advice, both scientific and 
otherwise. Thank you, Brooke, for always being there for me and being such a great friend.  
  
     Along with Brooke, several Lindquist lab members really helped me get started when I first 
joined the lab, including Jessica Brown and Julie Su; I am very grateful for their early help. I also 
must thank all of the members of the neurodegenerative disease subgroup, with whom I have 
extensively discussed this work. Dan Termine has been working other lipids related to α-syn-
induced toxicity and has provided advice for the work discussed in chapter two. The idea to 
work on the splice isoforms was developed through conversations with Chris Pacheco. As 
individually discussed in each chapter, I am very grateful for the many lab members who have 
read and provided feedback on portions of this thesis. Finally, I would like to thank Jessica 
Goodman, Catherine McLellan, Lauren Pepper, and Sebastian Treusch for their friendship and 
support. Finally, I would like to thank the scientific and administrative staff of the Lindquist lab 
past and present, Karen Allendoerfer, Robert Burger, Linda Clayton, Kate Harmon, and Audrey 
McArdle, for helping the lab run so smoothly. 
 
     Finally, my work has been greatly benefited from the work of three technicians in the lab, 
Melissa Duquette, who works hard and often thanklessly to keep our reagents and equipment 
well stocked; Yelena Freyzon, who helped me with projects that are not discussed here, and 
Lera Baru, who, together with Chee-Yeun Chung, helped with some neuronal work not 
discussed here.  
     
8 
 
     Beyond being a member of the Lindquist lab, for the past five and a half years, I have been 
fortunate to work in the Whitehead Institute. The combination of being surrounded by exciting 
science and wonderful people has made me look forward to coming into lab every day. I am 
extremely grateful to all of the support staff at the Whitehead – from the facilities department to 
procurement services, for their hard work and friendly attitude. I need to thank the sixth floor 
glass wash and media prep teams for making the lab work we do so seamless. I especially need 
to thank the head of our media prep team, Dubi Azubuine, for the countless plates and bottles of 
yeast media he has made for me.  
 
     I would like to thank my friends outside of the world of biology, for helping me to remember 
how to have a conversation that does not revolve around biology. I have also made great friends 
through the biology department and Whitehead who have provided much support, both career-
related and otherwise.  
 
     I am fortunate to have both been born into and married into a wonderful family, all of whom I 
must thank for their support and encouragement. I especially want to thank both of my 
grandmothers, for constantly showing their love and pride, and my grandfathers, who have 
taught me the importance of always being interested in learning something new. It is from their 
examples that I decided to pursue such an advanced degree.  Furthermore, from the time I met 
my husband, his family has welcomed me with open arms and been so encouraging to my 
career - I am so lucky to have gained them as my second family. 
 
      None of this would have been at all possible without the hard work of my parents, who 
always provided me with the best possible opportunities while I was growing up and always 
figured out what was best for me (even if it was science camp instead of basketball camp). Mom 
and Dad, thank you for everything – without you I would not be where I am today.  
  
     While my daughter Eva did not directly contribute to the progress of this work, there is no 
stronger motivation to get in to lab and work hard than knowing she is waiting for me to come 
home and play with her. Seeing what she could learn in her first year of life has also really put 
some pressure on me to keep up the pace. For that, I must thank her.  
    
     Finally, I need to thank my husband, Scott. Since we met over ten years ago, you have been 
my anchor, through good times and bad. You are a source of endless encouragement, from 
discussing experiments to reading every word of this thesis. I am so lucky to have met the love 
of my life so early in life and am so grateful to have gone through the past decade by your side. I 
can’t wait to see what the next decades bring.  
 
  
  
 
  
9 
 
JULIE SUZANNE VALASTYAN  
60 Wadsworth Street 
Apartment 24C 
Cambridge, MA 02142 
(732) 687-8448 
julie.valastyan@gmail.com 
 
Education  
  
2006-present Massachusetts Institute of Technology, Cambridge, MA 
 Doctor of Philosophy in Biology, expected June 2013 
 GPA: 5.0 (5.0 scale) 
 
2002-2006 Cornell University, Ithaca, NY 
Bachelor of Science in Biological Sciences, May 2006 
Emphasis in Neurobiology and Behavior, Molecular and Cell Biology  
GPA: 4.08 (4.0 scale) 
 
Research Experience 
 
2007-present Doctoral Thesis Research, Massachusetts Institute of Technology 
Advisor: Susan Lindquist, Ph.D. Topic: α-Synuclein-induced toxicity in 
Saccharomyces cerevisiae. 
 
2003-2006 Undergraduate Thesis Research, Cornell University 
Advisor: David Deitcher, Ph.D. Topic: Neurotransmitter release in Drosophila 
melanogaster. 
 
Publications   
 
Valastyan JS and Lindquist S. The Role of Protein Misfolding in Disease at a Glance.  
 Disease Models & Mechanisms. In preparation. 
 
Valastyan JS, Termine DJ, Lindquist S. α-Synuclein Splice Isoform Expression in S.    
cerevisiae Reveals Differential Sterol Sensitivities. In preparation. 
 
Termine DJ, Valastyan JS, Watson N, Clish CB, and Lindquist S. Lipidomic Profiling  
of α-Synucleinopathy Model Reveals the Contribution of Fatty Acid-Induced Toxicity to 
Pathobiology. In preparation.  
 
Treusch S, Hamamichi S, Goodman JL, Matlack KE, Chung CY, Baru V, Shulman JM,  
 Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans  
 DA, Bennett DA, Olofsson A, Dejager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist  
 S. (2011). Functional Links Between Aβ Toxicity, Endocytic Trafficking, and Alzheimer’s  
 Disease Risk Factors in Yeast. Science. 334 (6060), 1241-1245.  
 
Valastyan JS and Lindquist S. (2011). TorsinA and the TorsinA-Interacting Protein Printor     
     Have No Impact on Endoplasmic Reticulum Stress or Protein Trafficking in Yeast. PLoS     
     One. 6 (7), e22744- e22744. 
 
10 
 
Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan 
JS, Karger DR, Lindquist S, Fraenkel E. (2009). Bridging high-throughput genetic and 
transcriptional data reveals cellular responses to α-synuclein toxicity. Nature Genetics. 41 (3), 
316-323.  
 
Poster and Oral Presentations 
 
2011 Molecular & Cellular Biology of Lipids Gordon Conference – poster 
presentation 
  Valastyan JS, Termine D, and Lindquist S. Expression of α-Synuclein 
Isoforms in Saccharomyces cerevisiae Elicits Differential Sterol Sensitivities.  
 
 
2010  Bachmann-Strauss Foundation Grantee Presentations – oral presentation 
  Valastyan J and Lindquist S. Utilizing Saccharomyces cerevisiae to 
understand the relationship between torsinA, protein trafficking and folding 
defects and alpha-synuclein.  
 
 
2005  Neurobiology of Drosophila, Cold Spring Harbor – poster presentation 
  Beckenstein J and Deitcher D. The role of SNAP-25 and SNAP-24 during 
development. 
 
Conferences Attended 
 
2011 Gordon Conference – “Molecular & Cellular Biology of Lipids” 
2010 AAAS - “Bridging Science and Society” 
2008 Genetics Society of America - “Yeast Genetics and Molecular Biology” 
2005 Cold Spring Harbor Laboratory - “Neurobiology of Drosophila” 
 
Awards and Honors 
 
2010 Honorable Mention – Biology Teaching Award, MIT 
2006 Summa cum Laude with high honors in research, Cornell University 
2002-2006 Dean’s List (all semesters), Cornell University 
2004 Howard Hughes Medical Institute Research Scholar, Cornell University 
2004 Golden Key International Honour Society, Cornell University 
 
Teaching and Outreach Experience 
 
2011-2012 Demo Leader, Whitehead Institute One-Day Workshop for Girls 
2010-2011 Volunteer, Inspiring Minds: Meet Women in Science, Boston Museum of Science 
2010 Demo Leader, Center for Talented Youth: Science and Technology Series,  
  Whitehead Institute 
2010 Teaching Assistant, Introductory Biology, MIT 
2009-2010 Demo Leader, MIT Museum - multiple outreach events  
2008-2010 Tutor, Graduate Genetics, MIT  
2008 Tutor, Introductory Biology Laboratory and Undergraduate Genetics,  
      TechTutors 
2007-2012 Volunteer, Whitehead Partners: partnering scientists with local high school  
  teachers, Whitehead Institute 
2007, 2009 Volunteer, Cambridge Science Festival 
11 
 
2007 Teaching Assistant, Genetics, MIT 
 
Committees and Leadership Experiences 
 
2008-2010 Eastgate Executive Committee, President 
2007-2010 MIT Association for Biology Graduate Students/Student Member of MIT Biology  
  Graduate Committee 
2004-2006 Cornell University Biology Student Advisor 
2002-2006 Phi Sigma Pi, National Honor Fraternity 
  2005 Vice President 
  2004 Treasurer 
  2003 Public Relations/Inter-Chapter Relations Chair 
 
 
  
12 
 
  
13 
 
Table of Contents 
 
 Page 
Summary 3 
Dedication 5 
Acknowledgements  7 
Curriculum Vitae 9 
Table of Contents 13 
List of Figures and Tables 17 
 
Chapter One Introduction 19 
 
 Introduction 20  
 How Protein folding problems can cause disease 21 
  Improper localization 21 
  Improper degradation 22 
  Dominant negative mutations 23 
  Toxic novel function 25 
  Amyloid 26 
 The increasing prevalence of neurodegenerative disease 27 
 Parkinson’s disease 28 
 Alpha synuclein  32 
 Saccharomyces cerevisiae as a model organism for  33 
      neurodegenerative diseases  
 Using yeast to model synucleinopathy 35 
 α-Synuclein splice isoforms 41 
 Modeling early onset torsion dystonia 43 
 Concluding remarks 44 
 Acknowledgements 44 
 References  45 
  
Chapter Two Splice Isoform Studies Reveal that Sterol Depletion Relocalizes 57 
 and Enhances Toxicity of α-Synuclein 
   
 Abstract 58 
 Introduction 59 
 Results and Discussion  61 
  Splice isoforms of α-syn display different toxicity 61 
  Splice isoforms of α-syn display different localization 65 
 Tandem plasmid integration results in strains with similar  67 
  levels of toxicity 
  Isoforms of α-syn block secretion 69 
 α-Syn splice isoforms show differential response to OSH2 and  72 
           OSH3 overexpression  
  
14 
 
 α-SynFL and α-synΔ6, but not α-synΔ4, elicit sensitivity to  74 
           simvastatin and fluconazole 
 α-Syn-induced sensitivity to fluconazole can be attributed to an 77 
            increased trafficking block 
 Materials and Methods 79 
  Materials 79 
  Yeast strains and growth conditions 80 
  Plasmid construction 80 
  Single insertion PCR analysis 81  
  Real time PCR  82 
  Fluorescent microscopy 82 
  Spotting assays 83  
  Western blots 83 
  Secretion assay 84 
  Screening α-syn enhancers and suppressors 84 
  Statistics 84 
 Acknowledgements 85 
 References 85 
 
Chapter Three TorsinA and the TorsinA-Interacting Protein Printor Have no  89 
 Impact on Endoplasmic Reticulum Stress or Protein Trafficking 
 in Yeast 
 
 Abstract 90 
 Introduction 91 
 Results 94 
 Expression of torsinA in the yeast ER requires a yeast ER  94 
      localization signal 
 Expression of torsinA in yeast does not allow for recapitulation of  97 
      its roles in protein homeostasis and trafficking 
 Addition of the torsinA-interacting protein printor is not sufficient  101 
      to uncover the role of torsinA 
 Discussion 103 
 Material and Methods 105 
 Materials 105 
 Construction of plasmids 105 
 Yeast strains and growth conditions 106 
   Spotting assays  107 
   UPRE induction assays 107 
   Microscopy  107 
   BCP trafficking assays 107 
   Statistics  108 
 Acknowledgements 108 
 References 108 
 
 
15 
 
Chapter Four Conclusion: Lessons from Disease Models in Yeast 113 
  
 Introduction 114 
 Future directions: α-syn splice isoforms  118 
 Future direction: torsinA 122 
 Future directions: modeling human disease in yeast  124 
 Concluding remarks 125 
 Acknowledgements 126 
 References 126 
 
Appendix One Using Split-GFP to Study the Self-Interaction of -Synuclein 129 
 
 Abstract  130 
 Introduction 131 
 Results  132 
  Expressing α-syn tagged with split-GFP 132 
  Visualization of α-syn self-interactions 136 
 Discussion 138 
 Materials and Methods 140 
  Construction of plasmids 140 
  Yeast strains and growth conditions 140 
  Western blot 141 
  Microscopy 142 
 Acknowledgements 142 
 References 142 
 
16 
 
  
17 
 
Figure and Table List 
 
Chapter One  Introduction 19 
 
 Table 1.1  Summary of environmental toxins and genetic loci   31 
 associated with PD and what insight they provide into PD  
 progression 
 Figure 1.1  Summary of phenotypes associated with α-syn expression  40 
  in S. cerevisiae 
 
Chapter Two Splice Isoform Studies Reveal that Sterol Depletion Relocalizes 57 
 and Enhances Toxicity of α-Synuclein 
 
 Figure 2.S1 Diagram showing the primer placement for testing for  63 
  single integration of pRS plasmids. 
 Figure 2.1 Creation of strains with equal copy numbers of the α-syn  64 
  splice isoforms 
 Figure 2.2  α-Syn splice isoforms elicit different toxicities and  66 
  localization when expressed at the same level in  
  Saccharomyces cerevisiae  
 Figure 2.3 Higher levels of α-syn splice isoform expression leads to   68 
  higher toxicity and foci formation. 
 Figure 2.4 Splice isoforms elicit toxicity by similar, but not identical,  70 
  mechanisms. 
 Figure 2.S2 Fluorescent microscopy of α-syn-GFP-expressing cells in  71 
  addition to an empty vector or mKate-CHC1.  
 Figure 2.S3 High-throughput transformation of splice isoforms with  73 
  genetic modifiers of α-syn-induced toxicity produced  
  reproducible results 
 Figure 2.5 α-Syn splice isoforms show differential sensitivity to  75 
  changes in ergosterol levels.  
 
Chapter Three  TorsinA and the TorsinA-Interacting Protein Printor Have no  89 
   Impact on Endoplasmic Reticulum Stress or Protein Trafficking  
   in Yeast 
  
 Figure 3.1  TorsinA can be expressed in the endoplasmic reticulum of 96 
   yeast 
 Figure 3.2  TorsinA does not impact the unfolded protein response or  99 
  trafficking in yeast  
 Figure 3.3  TorsinA cannot rescue α-synuclein-induced toxicity in yeast 100 
 Figure 3.4  Coexpression of torsinA and printor does not uncover a  102 
  phenotype stemming from torsinA expression 
 Table 3.1  Primers used 106 
 
 
18 
 
Appendix One  Using Split-GFP to Study the Self-Interaction of α-Synuclein 129 
   
 Figure  A1.1 Summary of constructs used 134 
 Figure A1.2 Expression of split-GFP constructs 135 
 Figure A1.3 Visualization of α-syn-α-syn self-interactions 137 
 Table A1.1 Primers Used 140 
 
 
 
 
  
19 
 
 
 
 
 
 
 
Chapter One: 
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Parts of this chapter are in preparation for a review in Disease Models and Mechanisms. 
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Introduction 
 
     Proteins are one of the main cellular workhorses. According to the central dogma, the 
production of proteins involves the single step of translation. However, the unfolded amino acid 
chain that results from translation is far from biologically active. To function, a protein must first 
fold into its proper conformation. Although many aspects of folding are intrinsic to the biophysical 
properties of the protein itself, this process is still quite complex and susceptible to errors (Dill and 
MacCallum, 2012). Proteins consist of an elaborate arrangement of interior folds that collapse 
into a final structure, a process which is complicated by modest free energy gain associated with 
the correct folding of a protein as compared to its numerous misfolded states. Many misfolded 
proteins involved in disease contain one or more mutations that stabilize misfolded 
conformations. Furthermore, in vivo, protein folding is made even more difficult by the crowded 
environment of the cell, where proteins must assume their correct conformation while under 
constant barrage of neighboring molecules. These complications make it no surprise that many 
proteins assume the wrong conformation, often resulting in disease.  
     The cell has multiple methods for combating toxic misfolded proteins. First, chaperone 
pathways exist that either prevent proteins from misfolding in the first place or aid a misfolded 
protein in regaining its correct conformation (Hartl et al., 2011). Secondly, when it becomes 
clear that a misfolded protein cannot be properly refolded, systems exist to degrade these 
misfolded proteins (Nedelsky et al., 2008; Smith et al., 2011; Varshavsky, 2012).  However, 
dysfunction of these pathways is also associated with number of diseases.  
     I will start this chapter with some specific examples of how protein misfolding can lead to 
disease, including both diseases caused by the loss of function (due to protein mislocalization or 
degradation), as well as gain of function mechanisms (such as mutations that cause a toxic novel 
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function, dominant negative mutations, and amyloid accumulation). I will then focus on 
neurodegenerative diseases, specifically synucleinopathies, a class of disorders characterized by 
the accumulation of the protein alpha synuclein (α-syn). I will review how the yeast 
Saccharomyces cerevisiae has contributed to our understanding of the function and dysfunction 
of α-syn. This chapter serves as an introduction to understand the framework underlying my 
thesis studies using S. cerevisiae to study splice isoforms of α-syn, as well as attempts to model 
the pathobiology of torsinA, a protein implicated in a separate neurological disorder, early onset 
torsion dystonia.  
 
How protein folding problems can cause disease  
Improper Localization 
     Because many proteins that localize to specific organelles must fold correctly in order to be 
trafficked properly, mutations that destabilize the correct fold can lead to improper subcellular 
localization of otherwise functional proteins. -1-antitrypsin is a secreted protease inhibitor that, when 
mutated, leads to emphysema in a recessive, loss of function manner (Perlmutter, 2011). This occurs 
because mutant forms of this protein misfold and are retained in the endoplasmic reticulum (ER). If 
this protein is not secreted by hepatocytes into the circulation, it is unable to inhibit neutrophil elastase 
in the lung, which then causes extensive damage to this organ’s connective tissue. However, the 
consequences of this mutated protein are more complicated; it is also incorrectly localized at an organ 
level. Due to impared secretion, the misfolded protein accumulates in the ER of hepatocytes, its site of 
synthesis, and leads to liver damage in a dominant gain of function manner (Hidvegi et al., 2005; 
Lomas et al., 1992). While damage to the lungs can be controlled with enzyme replacement therapy 
(Mohanka et al., 2012), liver accumulation has proven a greater challenge but some progress is being 
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made. Because aggregates in the liver are degraded by macroautophagy, drugs that enhance 
autophagy, including rapamycin and carbamazepine,  have been shown to alleviate α-1-antitrypsin-
induced hepatic toxicity (Hidvegi et al., 2010). Other therapy has focused on directly blocking the 
aggregation of mutant -1-antitrypsin (Skinner et al., 1998). 
 
Improper degradation 
     While degradation systems are essential for preventing the accumulation of non-functional 
misfolded proteins, they sometimes destroy proteins that, while mutant, could still function. For 
example, cystic fibrosis is caused by mutations in the plasma membrane chloride channel CFTR. 
The most common mutation of CFTR that cause cystic fibrosis is deletion of F508. This mutation 
destabilizes the protein causing it to misfold and be targeted for degradation (Qu et al., 1997); 
however, conditions that allow CFTRF508 to be folded properly and trafficked, such as lower 
growth temperature, show that the mutant protein can partially function (Denning et al., 1992). 
This finding prompted the discovery of a chemical chaperone of CFTRF508, or a small 
molecule that can allow a mutant, misfolded protein to regain its properly folded form (Brown 
et al., 1996). More recent work has uncovered the role of a multiprotein complex containing 
HSP90 and its co-chaperone AHA1 in CFTR degradation (Wang et al., 2006). Remarkably, upon 
knockdown of AHA1, CFTR ΔF508 becomes not only more stable, but its function can also be 
partially restored, suggesting that inhibition of chaperone systems may be therapeutically 
beneficial to patients with this mutation (Wang et al., 2006).  
      A second example is provided by Gaucher's disease, the most common lysosomal storage 
disease (Cox and Cachon-Gonzalez, 2011; Futerman and van Meer, 2004). It is caused by a 
variety of mutations in beta-glucosidase, leading to the buildup of the lipid, glucosylceramide. 
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The symptoms of Gaucher’s disease vary widely (Grabowski, 2008) and, while this variability is 
not fully understood, it is thought to be related to extent of degradation of beta-glucosidase in 
the ER (Ron and Horowitz, 2005). Depending on the extent of ER processing, some fraction of 
the protein can be correctly processed, trafficked to the lysosome, and function, even in 
individuals carrying the disease-associated mutations. Currently, the most developed treatment 
for Gaucher’s disease is enzyme replacement therapy, which is expensive and not curative 
(Grabowski, 2008). Therefore, there is great hope that a useful intervention for Gaucher’s 
disease could be upregulation of chaperones that assist in the correct folding of beta-
glucosidase (Sawkar et al., 2006). Indeed, both drugs that activate the unfolded protein 
response and chemcial chaperones that directly interact with and stabilize mutant beta-
glucosidase have demonstrated efficacy in patient-derived cells (Sawkar et al., 2005; Sawkar et 
al., 2002). 
 
Dominant negative mutations 
     A third way by which protein misfolding can cause disease is through a dominant negative 
mechanism. This occurs when a mutant protein antagonizes the function of the wild type (WT) 
and a phenotype results due to loss of protein activity even in a heterozygote. One example of 
this mechanism related to protein misfolding is epidermolysis bullosa simplex, a skin disorder 
characterized by severe blistering in response to injury. It is associated with mutations in the 
keratin genes KRT5 or KRT14. Keratin forms long intermediate filaments that provide structure 
to the epidermis of the skin (Chamcheu et al., 2011). Disease-associated mutations in keratin 
cause the protein to misfold and aggregate, particularly in response to mechanical stress 
(Coulombe et al., 2009; Russell et al., 2004; Werner et al., 2004). Because a filament is 
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constructed of multiple keratin molecules, each filament tends to contain both WT and mutant 
protein in a heterozygote individual. The dominant nature of the disease is therefore explained 
by the fact that the mutant protein present in these filaments does not function properly, thus 
compromising the function of the entire filament. Like several other diseases discussed here, 
recent research has found chemical chaperones that may prevent the aggregation of mutant 
keratin and alleviate symptoms of the disease (Chamcheu et al., 2012). 
     A second example of dominant negative mutations that involve protein misfolding and 
predispose to disease is mutations in the homotetrameric transcription factor, p53. These 
mutations are one of the most common genetic alterations seen in cancer (Friedman et al., 
1993). This is because p53 is responsible for regulating a host of pathways involved in 
maintaining genome integrity, including apoptosis, DNA damage repair, cell cycle regulation, 
and metabolism (Freed-Pastor and Prives, 2012). In the absence of stress, p53 is rapidly 
degraded by the proteosome in a process dependent on the ubiquitin ligase MDM2 (Kubbutat et 
al., 1997). In response to stresses like DNA damage, p53 is stabilized and able to stimulate 
transcription of its target genes. Many of the most common oncogenic mutations in p53 disrupt 
the core domain of the protein, preventing it from assuming its correctly folded conformation. 
These mutations have two effects. First, mutant p53 is still able to associate with other p53 
monomers; however, the resulting tetramer does not function correctly, regardless of whether 
or not a WT copy of p53 is also present (Milner and Medcalf, 1991; Milner et al., 1991). Because 
of this, mutant p53 acts in a dominant negative manner; even in a heterozygote, most tetramers 
are dysfunctional. Secondly, mutant p53 is unable to interact with MDM2, and thus is more 
stable. This inappropriate accumulation of the mutant form of the protein makes it even less 
likely that a tetramer comprised solely of WT p53 will form. One family of small molecules 
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currently undergoing clinical trial for cancers dependent on p53 dysfunction are Nutlins. These 
compounds prevent MDM2 from interacting with and promoting degradation of WT p53, 
increasing the probability of formation of WT tetramers (Vassilev et al., 2004). Recently, small 
molecules that directly bind and restore WT function of mutant p53 have also been found 
(Gavrin et al., 2012). 
 
Toxic novel function  
     Another way protein misfolding can cause a dominant phenotype is by allowing a protein to 
acquire a conformation that exerts a toxic novel function. One example is apolipoprotein E 
(APOE), a lipid transport molecule. One particular allele of APOE, APOE4, is found in at least one 
copy in 65-80% of patients with the disease (Farrer et al., 1997). The mutation in APOE4 
stabilizes a misfolded conformation of the protein; the WT protein has an extended domain that 
is compromised by an extra salt bridge in APOE4 (Dong and Weisgraber, 1996; Dong et al., 
1994). This interaction changes the lipid affinity of APOE4 (Dong and Weisgraber, 1996; Dong 
et al., 1994), leads to disruption of mitochondrial function (Chen et al., 2011) and impairs 
neurite outgrowth (Nathan et al., 1994). It is also associated with increased levels of Aβ, the 
peptide that aggregates in brains of patients with Alzheimer’s disease (Ma et al., 1994). This 
strongly implicates misfolded APOE in the pathogenesis of Alzheimer’s disease. Due to the 
specific change in APOE4 structure, small molecules that prevent formation of the extra salt 
bridge may provide a therapeutic strategy for correcting the dysfunction of this protein. A 
recent study utilized a FRET-based assay to identify structure correctors that prevented APOE4 
from forming the aberrant salt bridge that stabilizes its misfolded form (Brodbeck et al., 2011).  
26 
 
Compounds that corrected APOE4 misfolding also rescued APOE4-associated mitochondrial 
dysfunction and inhibition of neurite outgrowth. 
     A second example of mutation related to protein misfolding that leads to a toxic novel 
function for a protein is seen in v-SRC. This mutant form of this nonreceptor tyrosine kinase 
lacks an inhibitory phosphorylation site. While oncogenic SRC mutants have only been 
demonstrated in chicken fibrosarcoma, the lessons learned apply to other members of the SRC 
kinase family that are relevant to human cancers. Although v-SRC is constitutively active, it is 
also inherently less stable and requires the chaperone HSP90 for its maturation and proper 
localization; in contrast, WT SRC is much less HSP90-dependent (Bijlmakers and Marsh, 2000; 
Whitesell et al., 1994; Xu and Lindquist, 1993; Xu et al., 1999). Importantly, the activity of many 
oncogenic kinases, including other SRC family kinases, BCR-ABL, and BRAF, all display an 
increased requirement for assistance from the HSP90-based chaperone machinery [for recent 
review, see (Trepel et al., 2010)]. These finding have led to extensive efforts to understand and 
target chaperone function in the treatment of cancers (Mendillo et al., 2012; Whitesell et al., 
2012)  
 
Amyloid  
     No review of misfolded proteins and disease would be complete without discussion of the 
ability of stable amyloid fibers to accumulate and contribute to a variety of diseases. Amyloid 
pathogenesis differs from the mechanisms described earlier in that there are a wide range of 
diseases associated with different proteins, all of which accumulate as very stable and insoluble 
beta sheet fibers called amyloid. These diseases range from neurodegenerative disorders 
(including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease) to amyloidoses 
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(such as familial amyloid polyneuropathy and primary systemic amyloidosis) (Caughey and 
Lansbury, 2003; Chiti and Dobson, 2006). In some cases, such as cataracts, disease is directly 
caused by amyloid fibril accumulation. In other cases, especially the neurodegenerative 
diseases, this is less clear. Recent evidence favors the theory that it is lower order oligomers that 
are responsible for disrupting cellular function and the amyloid deposits may be a protective 
mechanism that the cell uses to sequester these toxic species. Several of these proteins are also 
capable of forming pore-like structures that are hypothesized to disrupt membrane integrity, 
which is an additional potential toxicity mechanism (Lashuel et al., 2002). As previously 
discussed for α-1-antitrypsin deficiency, when pathogenesis is caused by the accumulation of 
protein aggregates, an attractive therapeutic strategy is to limit disease by blocking aggregate 
formation. Due to the role of amyloid accumulation in such a wide range of diseases and the 
shared pathway to fibril formation, much work has gone into creating therapeutics that target 
this amyloid fold, as opposed to targeting specific proteins. Indeed, antibodies have now been 
developed that recognize both amyloid fibrils and oligomers; an oligomer-specific antibody is 
able to block the toxicity of multiple types of oligomers in vitro. (Glabe, 2004; Kayed et al., 
2003). Recent work has turned to developing antibodies that recognize both conformation and 
sequence, possibly allowing for more targeted therapeutics (Perchiacca et al., 2012). Small 
molecules that prevent aggregate formation (Ehrnhoefer et al., 2008) or enhance their 
degradation (Rubinsztein et al., 2007) have also been discovered.  
 
The increasing prevalence of neurodegenerative disease 
     As mentioned above, neurodegenerative diseases are a major class of protein folding diseases 
and will be a major emphasis of the remainder of this thesis. With the rise of average lifespan of 
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individuals in developed countries, these diseases, associated with advancing age, are becoming 
increasingly prevalent. As of 2012, 12.5% of the American population over 65 is living with AD 
and another 2% are living with PD (www.alz.org). Even more staggering is the financial cost 
associated with these diseases. In the United States alone, the combined annual direct and 
indirect costs associated with AD are $183 billion (www.alz.org) and with PD are nearly $25 
billion (www.pdf.org). Furthermore, as the baby boomer population continues to age, the costs 
associated with these late-onset diseases are expected to further skyrocket. For example, it is 
estimated that the cost of AD alone will be $1.1 trillion by 2050, not even accounting for 
inflation (www.alz.org). The need to find more effective and cheaper means of treating these 
diseases is desperate, and to accomplish this, we must gain a stronger understanding of their 
underlying causes.  
 
Parkinson’s disease 
     The second most prevalent neurodegenerative disease is PD, a major topic covered in this 
thesis. PD is the main cause of parkinsonism, a syndrome that presents with four main 
symptoms: resting tremor, rigidity of movement, bradykinesia/akinesia, and postural instability 
(Dauer and Przedborski, 2003). The majority of these symptoms are due to degeneration of 
dopaminergic neurons in the substantia nigra pars compacta, a region of the brain essential for 
motor control; however, other regions of the brain and autonomic nervous system degenerate 
as well, which account for the non-motor symptoms, including constipation, sleep disorders, 
anosmia, and depression (www.pdf.org). Unfortunately, by the time most symptoms present, 
there is already significant degeneration of various areas of the brain and the autonomic 
nervous system, making treatment difficult since there is no way to regain lost neurons. Beside 
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loss of specific brain regions, a striking feature of post-mortem brains of individuals with PD is 
the intracellular aggregates of proteins termed Lewy bodies (LB) and Lewy neurites. These 
accumulate in the remaining neurons of the affected brain regions and are named for Frederic 
Lewy, who first described the aggregates in 1912 (Rodrigues e Silva et al., 2010; Spillantini et al., 
1997). 
     The majority of cases of PD and other parkinsonisms are sporadic, having no defined 
environmental or genetic cause. However, the small numbers of environmentally implicated or 
inherited cases have provided significant insight into the mechanisms of parkinsonism 
progression (Table 1). For example, exposure to the herbicide paraquat increases an 
individual’s risk of developing PD, with an odds ratio confidence interval of 1.4-4.7 (Liou et al., 
1997; Tanner et al., 2011). Paraquat acts as an oxidizing agent, which has led to examination of 
the role of superoxide radicals in PD progression (Bus et al., 1974). Environmental toxins have 
also drawn attention to mitochondrial complex I, as the street drug contaminant MPTP and the 
insecticide rotenone [odds ratio confidence interval 1.3-4.7 (Tanner et al., 2011)] both have 
been linked to environmentally related cases of parkinsonism and have been shown to inhibit 
this enzyme complex (Davey and Clark, 1996; Nicklas et al., 1985). MPTP was synthesized in the 
As and tested in primates as a treatment for a number of diseases; however, these tests were 
halted when the primates developed parkinsonisms. Interest in MPTP arose again from studies 
of drug users who developed parkinsonism symptoms upon exposure to contaminated drugs 
(Langston et al., 1983) and is now often used to model parkinsonism in vivo, while rotenone has 
mostly been used to create cell culture models (Betarbet et al., 2000). 
     PD is part of a spectrum of diseases termed parkinsonian disorders, all of which result in 
some loss of movement control, which can be due to degeneration of multiple brain regions and 
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can be combined with a wide variety of other symptoms, including dementia (Bohlhalter and 
Kaegi, 2011). Sixteen different PARK alleles have been associated with the familial cases of these 
disorders. Studies of these genes have provided insight into mechanisms driving the 
progression of these diseases. For example, four genes thought to contain causative alleles for 
genetically-linked cases of parkinsonism, parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7), and 
HTRA2/Omi (PARK13), have been linked to regulating levels of oxidative stress and regulating 
of mitochondrial function (Bonifati et al., 2003; Darios et al., 2003; Palacino et al., 2004; Strauss 
et al., 2005; Valente et al., 2004a). Furthermore, eleven other PARK loci have been identified as 
genes important in familial PD and related disorders and we are learning more and more about 
the genes important for these heritable forms of the disease (Table 1.1) (Corti et al., 2011). For 
example, mutations in the metal transporter ATP13A2 are associated with an autosomal 
recessively inherited form of parkinsonism with dementia (Gitler et al., 2009; Ramirez et al., 
2006; Rentschler et al., 2012). Sharing ties to metal homeostasis, miners and welders who are 
exposed to heavy metals have an increased risk of parkinsonism (Racette et al., 2001; Sanchez-
Ramos et al., 2011), tying cation exposure, especially manganese (Perl and Olanow, 2007), to 
development of parkinsonism. Additionally, parkin and FBXO7, the latter of which was found in 
a study looking for genes associated with Parkinsonian-pyramidal syndrome as opposed to 
canonical PD, have both been implicated in ubiqitination, which fits with the stereotypic role of 
protein accumulation in PD (Shimura et al., 2000; Shojaee et al., 2008). However, the most 
extensively studied gene implicated in PD progression is α-syn.  
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Environmental  
Toxin  Insight into PD 
MPTP 
Mitochondrial Involvement Rotenone 
Paraquat 
Heavy Metal Exposure Role of Heavy Metals 
  
Genetic  
PARK Locus  Gene Cellular Role  
PARK1/PARK4 SNCA (α-syn) Synaptic function 
PARK2 Parkin Ubiquitin ligase and mitochondrial function 
PARK3 SPR Dopamine synthesis 
PARK5 UCHL1 Deubiquitinating enzyme 
PARK6 PINK1 Mitochondrial function and oxidative stress 
PARK7 DJ-1 Chaperone and oxidative stress 
PARK8 LRRK2 Kinase 
PARK9 ATP13A2 Metal homeostasis and lysosome function 
PARK10 Unknown Unknown 
PARK11 GIGYF2 Vesicular transport 
PARK12 Unknown Unknown 
PARK13 HTRA2/Omi Mitochondrial function 
PARK14* PLA2G6 Lipid Metabolism 
PARK15* FBXO7 Ubiquitin pathway 
PARK16 Unknown Unknown 
  
Table 1.1. Summary of environmental toxins and genetic loci associated with PD and the 
insight they provide into PD progression. Underlined genes and/or cellular roles are not 
completely defined. *PARK14 and PARK15 were found based on roles in adult-onset levodopa-
responsive dystonia-parkinsonism and Parkinsonian-pyramidal syndrome, respectively. (Ash et 
al., 2010; Corti et al., 2011; Dauer and Przedborski, 2003; Paisan-Ruiz et al., 2009; Sanchez-
Ramos et al., 2011; Shojaee et al., 2008). 
  
32 
 
Alpha synuclein  
     α-Syn is prominently linked to PD progression, along with a number of other 
neurodegenerative diseases collectively termed synupcleinopathies. This association has drawn 
on two grounds. First, α-syn is a major component of LB (Spillantini et al., 1997). Second, as 
shown in Table 1, genetic variants at the α-syn locus are associated with familial forms of 
synucleinopathies. Two point mutants, A53T and A30P, are associated with familial PD, while a 
third point mutant, E46K, is linked with dementia with Lewy bodies (Kruger et al., 1998; 
Polymeropoulos et al., 1997; Zarranz et al., 2004). Duplications and triplications of α-syn were 
shown to cause synucleinopathy and lower its average age of onset (Chartier-Harlin et al., 2004; 
Singleton et al., 2003). Furthermore, multiple SNPs associated with increased risk for sporadic 
PD have been linked to the α-syn locus (Mizuta et al., 2006). 
     Both in vitro and in vivo studies have shed light on structural properties of α-syn, as well as its 
endogenous function. It is a small, 14 kDa protein that is natively unfolded in an aqueous 
environment. In the presence of lipids, the N-terminus of α-syn forms amphipathic alpha 
helices, which associate with lipids (Davidson et al., 1998). This property is due to the presence 
of approximately six imperfect sequence repeats (KTKEGV) that, when oriented as an alpha 
helix, create an amphipathic distribution of the amino acids (Auluck et al., 2010). However, even 
in a lipid environment, the C-terminus of the protein remains unfolded (Eliezer et al., 2001). The 
C-terminus is thought to be important for protein-protein interactions of α-syn. Between the N- 
and C-termini is a region termed the NAC domain. This region was originally identified as the 
Non-Amyloid Component of amyloid deposits purified from brains of patients with AD (Ueda et 
al., 1993). Part of this region, especially amino acids 71-82, is important for the α-syn self-
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interactions and toxicity (Giasson et al., 2001). Removal of this region, which makes α-syn more 
similar to its paralog β-synuclein (β-syn), abolishes its fibrilization ability. 
     As suggested by its name, α-syn localizes to the synaptic region of a neuron, as well as the 
nucleus (Maroteaux et al., 1988). While its nuclear role is not well understood, we are beginning 
to understand that α-syn plays a role in regulating vesicle fusion at the synapse. As will be 
discussed below, work in a number of model organisms, including the yeast, Saccharomyces 
cerevisiae, were important for elucidating this function of α-syn.  
 
Saccharomyces cerevisiae as a model organism for neurodegenerative diseases 
     While it may initially seem like an unconventional choice for modeling neurodegenerative 
disease due to its lack of a nervous system, we have learned a great deal about the proteins 
involved in these disorders through studies in the single cell yeast, S. cerevisiae. There are many 
benefits to using S. cerevisiae as a model organism for studying cellular toxicity (Khurana and 
Lindquist, 2010). S. cerevisiae share many of the traits of other single-celled organisms, such as 
rapid generation time and inexpensive reagents for growth and manipulation. Furthermore, 
they have a compact genome and can exist as either a diploid or a haploid. This makes S. 
cerevisiae genetically tractable, with simple methods for expressing exogenous genes and 
creating deletion mutants for hypothesis-driven research, as well as many libraries available for 
high-throughput chemical and genetic analyses. This has allowed extensive characterization of 
the protein interactome of S. cerevisiae, which has been an invaluable tool for systems biology 
and allows for detailed dissection of pathways involved in a number of cellular processes 
(Petranovic and Nielsen, 2008). However, S. cerevisiae differ from bacteria in that they are 
eukaryotes, so they share similar subcellular compartments with higher organisms and display 
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significant conservation of fundamental cellular processes such as secretion, protein 
homeostasis, and mitochondrial function.  
     There has been a long history of learning about disease progression and complex processes 
through studies in S. cerevisiae, such as the function of the cancer-related protein v-src (Brugge 
et al., 1987) and the ability of HSP90 to modulate its toxicity (Xu and Lindquist, 1993), and the 
role of Bcl and Bax in apoptosis (Khoury and Greenwood, 2008). Furthermore, the scope of 
knowledge uncovered by studying proteins involved in many of the major neurodegenerative 
diseases in S. cerevisiae is remarkable.  
     One of the first yeast models of neurodegenerative disorders was the use of S. cerevisiae to 
examine proteins involved in a family of diseases termed poly(Q) expansion disorders. The 
most common member of this family is Huntington’s disease, in which an extension of 
glutamine repeats in the protein Htt is directly associated with the severity of the disorder (The 
Huntington's Disease Collaborative Research Group, 1993). Similar to α-syn in 
synucleinopathies, Htt forms intracellular aggregates in brains of patients with Huntington’s 
disease (DiFiglia et al., 1997). In a S. cerevisiae model, the first exon of Htt was expressed with 
polyQ tracts of varying lengths. Similar to the correlation between repeat length and disease 
severity, the more CAG repeats added to the protein, the more toxic expression of the protein 
was to S. cerevisiae (Giorgini et al., 2005). Furthermore, as the length of the CAG repeats was 
increased, the protein formed intracellular aggregates, reminiscent of those seen in the neurons 
of patients with Huntington’s disease (Krobitsch and Lindquist, 2000). Once this model was 
established, it was used in a high-throughput screen to find small molecules capable of 
reversing the toxicity (Ehrnhoefer et al., 2006; Zhang et al., 2005) and genetic screens to identity 
genes that, when deleted, suppress (Giorgini et al., 2005) or enhance (Willingham et al., 2003) 
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Htt-induced toxicity. A variety of findings uncovered in S. cerevisiae studies have been validated 
in higher organism models (Khurana and Lindquist, 2010). Since using S. cerevisiae to study 
polyQ-induced toxicity, this concept has been expanded to employ yeast to study TDP-43 
(implicated in amyotrophic lateral sclerosis) (Johnson et al., 2008), Aβ (implicated in AD) 
(Treusch et al., 2011), and α-syn.  
 
Using yeast to model synucleinopathy 
     In 2003, two papers introduced a yeast model of α-syn-induced toxicity (Outeiro and 
Lindquist, 2003; Willingham et al., 2003). In this model, α-syn is expressed under the control of 
a galactose-inducible promoter. When expressed at a low level, α-syn was nontoxic and 
associated with the plasma membrane (Outeiro and Lindquist, 2003) (Figure 1.1). This 
localization fits with the lipophilic nature of the amphipathic helices of the N-terminus of α-syn. 
As α-syn was expressed at higher levels, the protein elicited cytotoxicity and began to localize to 
intracellular foci, reminiscent of LB (Figure 1.1). Immuno-electron microscopy (immunoEM) 
discerned that these foci were comprised of clumps of secretory vesicles decorated with α-syn 
(Gitler et al., 2008; Soper et al., 2008).  
     Figure 1.1 provides a summary of the phenotypes associated with α-syn expression in the 
three main strains created in our lab – NoTox, IntermediateTox (IntTox), and HighTox (HiTox), 
which express increasing levels of α-syn and, as implied by the names, show increasing levels of 
α-syn-induced toxicity. Throughout this work, these names will be used to describe strains 
showing the corresponding level of toxicity.  
     Results from a high-throughput screen shed light on the probable mechanisms involved in 
the accumulation of secretory vesicles upon expression of α-syn (Cooper et al., 2006). Almost all 
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genes in the yeast genome were tested to find genes that, when overexpressed, either enhanced 
or suppressed the toxicity elicited by α-syn expression. The largest class of modifiers uncovered 
from this screen was genes involved in endoplasmic reticulum (ER)-to-Golgi trafficking. Taken 
with the fact that α-syn reaches the plasma membrane by traveling on secretory vesicles 
originating from the ER (Dixon et al., 2005), it was hypothesized that α-syn is causing a block in 
ER-to-Golgi trafficking, thereby leading to the accumulation of vesicles and accounting for at 
least part of the toxicity mediated by α-syn. Indeed, expression of α-syn blocks trafficking of the 
endogenous yeast protein CPY, which normally traffics from the ER to the Golgi to the vacuole, 
acquiring experimentally discernible modifications in the process.  
     Importantly, this finding echoes those obtained from higher organisms. First, homologs of the 
hits from the overexpression screen, including those involved in ER-to-Golgi trafficking, were 
able to modify α-syn-induced toxicity in higher organism models of synucleinopathy. 
Furthermore, the fact that α-syn blocks ER-to-Golgi trafficking is consistent with the phenotype 
that results from α-syn deletion and overexpression in higher organisms. While deletion of α-
syn in mice does not elicit any major phenotypes, electrophysiology studies uncovered that 
inappropriately large amounts of neurotransmitter are released in response to various stimuli, 
suggesting that the absence of α-syn allowed more synaptic vesicles to fuse with the presynaptic 
membrane. This implicates α-syn in stalling these vesicles (Abeliovich et al., 2000). 
Overexpression of α-syn in PC12 cells elicits the opposite response – lower quantities of 
dopamine are released from cells overexpressing α-syn than the wild type counterpart (Larsen 
et al., 2006).  
     Other phenotypes associated with α-syn overexpression can also be compared to features of 
synucleinopathies. Higher expression of α-syn in yeast elicited mitochondrial dysfunction 
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(Buttner et al., 2008; Flower et al., 2005; Su et al., 2010), as observed by higher levels of ROS 
production and downregulation of mitochondrially related genes as revealed by microarray 
analysis. This is reminiscent of the fact that other PD-related genes, such as parkin and PINK1, 
have been ascribed mitochondrial functions (Clark et al., 2006; Kitada et al., 1998; Valente et al., 
2004b). Furthermore, a small molecule screen uncovered a compound that rescued yeast from 
α-syn-induced toxicity and reversed the mitochondrial signature (Su et al., 2010). This 
compound could rescue not only animal models of α-syn-induced toxicity, but also toxicity 
induced by treating rat midbrain neuronal culture with rotenone. This work helped to both 
prove the relevance of the model and show connections between α-syn and mitochondrially 
related genes and toxins implicated in PD progression, providing evidence that these were 
interrelated processes and not entirely separate means to induce PD. 
     The yeast model also has been helpful in showing ties between α-syn and another PD-related 
gene, PARK9 (Gitler et al., 2009; Ramirez et al., 2006), which encodes the metal transporter 
ATP13A2. The yeast homolog of this gene, later named YPK9, was discovered in the previously 
described overexpression screen as a suppressor of α-syn-induced toxicity. More detailed 
analysis revealed that PARK9 homologs could rescue higher organism models of α-syn-induced 
toxicity and uncovered that YPK9 plays a role in manganese homeostasis. Intriguingly, while 
manganese exposure and mutations in PARK9 had been tied to parkinsonism, this form of the 
disease shows no Lewy bodies and affects a different brain region than classical PD (Perl and 
Olanow, 2007; Smyth et al., 1973). There were no previously established ties between metal 
levels and α-syn, and therefore, the yeast model was able to provide a novel link between α-syn-
induced toxicity, PARK9, and manganese induced parkinsonism.  
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     Given the physical association of α-syn with lipids, it is not surprising that α-syn induces lipid-
related phenotypes in yeast. The earliest description of α-syn expression in yeast reported an 
increase in lipid droplet formation in yeast expressing a toxic level of α-syn (Outeiro and 
Lindquist, 2003). Furthermore, the toxicity induced by α-syn expression is sensitive to the lipid 
environment in yeast, as the toxicity of α-syn-expressing cells is enhanced by inhibition of 
elongases required for the generation of very long chain fatty acids (Lee et al., 2011). Finally, the 
local lipid environment may be important for the formation of α-syn foci – one group showed an 
increased concentration of phosphatidic acid and that increases in acidic phospholipids 
increased the ability of α-syn to form foci (Soper et al., 2011), while another report found that α-
syn associated with lipid rafts (Zabrocki et al., 2008).  
     Lipid rafts are highly enriched in sterols. Higher organisms, including humans, utilize 
cholesterol as their main sterol; however, in yeast, this role is fulfilled by ergosterol. Thorough 
analysis of two high-throughput analyses also revealed the importance of ergosterol in α-syn-
induced toxicity. A flow algorithm, named ResponseNet, analyzes connections between 
differentially expressed genes found in microarray analyses and modifiers in an overexpression 
screen resulting from the same cellular perturbation (Yeger-Lotem et al., 2009). This is 
especially important because, in most cases, the hits from these two analyses are mutually 
exclusive, as hits from genetic screens tend to be biased toward transcriptional and regulatory 
proteins that can affect entire pathways, while microarray analyses tend to favor metabolic 
proteins involved in the response of a perturbation. ResponseNet was able to highlight genetic 
pathways affected by α-syn expression. One path highlighted by this algorithm was genes 
involved in ergosterol biosynthesis. Indeed, α-syn-expressing cells were found to be 
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hypersensitive to treatment with lovastatin, an inhibitor of HMG-CoA reductase, which an 
upstream biosynthetic gene a gene upstream in ergosterol synthesis. 
     There is already some evidence from human studies to suggest that this impact involving 
sterols is medically relevant for humans; however, the current state of the field is complicated 
by contradicting information. One study associated occurrences of PD with reduced levels of 
low-density lipoprotein (LDL) cholesterol (Huang et al., 2008). A case study also reported on a 
patient who developed reversible PD-related symptoms upon treatment with a statin (Muller et 
al., 1995). Conversely, another study found slower disease progression in PD patients on statins 
(Wolozin et al., 2007). However, this latter study may be confounded by the fact that individuals 
on statins have high levels of cholesterol to begin with or that statins affect a number of 
cholesterol-independent pathways (Goldstein and Brown, 1990) that may confound these 
studies. Nevertheless, this suggests an interesting relationship between cholesterol and PD 
progression.  
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(a) 
 NoTox IntTox HiTox 
Foci Formation Absent Moderate High 
Growth Defect Absent Moderate High 
Vesicle Accumulation Mild Moderate High 
Mitochondrial Defect Absent Mild Present 
Lipid Droplet Accumulation Absent Mild Present 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Summary of phenotypes associated with α-syn expression in S. cerevisiae. (a). 
Table describing the cellular phenotypes associated with three main strains of S. cerevisiae with 
increasing levels of α-syn expression. (b) Fluorescent and electron microscopy of the strains. 
m=mitochondria, n=nucleus, v=vacuole, pm=plasma membrane, *=accumulation of vesicles. 
Adapted from (Cooper et al., 2006; Gitler et al., 2008; Outeiro and Lindquist, 2003; Su et al., 
2010) 
 
 
α-Syn Expression 
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α-Synuclein splice isoforms 
     The second chapter of this thesis highlights work studying the properties of two splice 
isoforms of α-syn in yeast. α-Syn is comprised of seven exons (Beyer and Ariza, 2012; Xia et al., 
2001). The first two exons exists entirely in the 5’ untranslated region of the protein, and thus 
was not used in any S. cerevisiae-based α-syn studies as endogenous S. cerevisiae regulatory 
sequences were used instead. Exons three and four form the majority of the N-terminus of the 
protein. All three disease-related point mutations of α-syn are found within these two exons, 
with A30P located in the third exon and E46K and A53T in the fourth. The remainder of the N-
terminus and the NAC domain are encoded by exon five. Exon six and exon seven form the C-
terminus and 3’ untranslated region (Beyer, 2006). Four isoforms of α-syn have been identified 
in humans, α-syn140 (full length), α-syn126 (lacking exon four), α-syn112 (lacking exon six), 
and α-syn98 (lacking exons four and six) (Beyer et al., 2008a; Campion et al., 1995; Ueda et al., 
1994).  
     Recent work has highlighted the pathophysiological relevance of these splice isoforms. 
Multiple studies have shown variation in levels of these splice isoforms in patients with 
synucleinopathies (Beyer et al., 2008a; Beyer et al., 2008b; Beyer et al., 2006; Beyer et al., 2004). 
Furthermore, these variations differ between distinct synucleinopathies. For example, in 
patients with dementia with Lewy bodies, levels of α-syn140 (full-length) and α-syn126 
significantly decreased, while levels of α-syn112 and α-syn98 significantly increased (Beyer et 
al., 2008a; McLean et al., 2011). In PD, levels of all forms of α-syn increased, although to different 
extents (Beyer et al., 2008a; McLean et al., 2011). Although all of these studies are constrained 
by low sample size, the repeated reports of variation in α-syn isoform levels between patients 
and controls suggest there is some correlation between splicing and disease onset. 
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Furthermore, variability in the 3’ untranslated region of α-syn, including risk alleles for sporadic 
PD, is associated with increased levels of α-syn splicing, further suggesting that variability in 
splice isoform level may be associated with PD (McCarthy et al., 2010).  
     There are also ties between α-syn splicing and toxin-driven models of PD. Treatment of SH-
SY5Y dopaminergic cells with either MPP+ (the toxic byproduct of MPTP) or rotenone, two of 
the environmental toxins used to model PD, leads to an increase in exon five splicing (Kalivendi 
et al., 2009). Also, expression of α-syn98 renders PC12 cells more sensitive to rotenone and 
generates higher levels of reactive oxygen species than expression of α-syn140 (Ma et al., 2011).  
     Previous work on α-syn sequence truncations and mutants in S. cerevisiae allowed us to 
generate hypotheses on the properties of the various α-syn splice isoforms. One study examined 
a panel of α-syn point mutants for their toxicity and ability to bind to the plasma membrane in S. 
cerevisiae (Volles and Lansbury, 2007). They found a direct relationship between the mutant’s 
ability to bind to the plasma membrane and its ability to induce toxicity, suggesting that lipid 
binding is important for the mechanism by which α-syn impedes cellular growth. Removal of a 
portion of the NAC region (AA 71-82) from α-syn (or expression of β-syn) destroyed the 
protein’s ability to form foci and induce toxicity, but did not affect membrane binding (Soper et 
al., 2008). This work suggests that the biophysical properties of α-syn could be studied in S. 
cerevisiae and that the different isoforms may elicit differential localization and potential to 
induce toxicity.  
     S. cerevisiae rarely utilize splicing as a mechanism of genetic regulation (Dujon, 1996). 
Therefore, I generated expression constructs containing the alternatively spliced versions of α-
syn by overlap extension PCR. These constructs were then integrated into S. cerevisiae genome 
to study the biophysical properties of the proteins and the mechanism by which each isoform of 
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α-syn induces toxicity. This study uncovered an interesting phenotype concerning differential 
sensitivity to lipid homeostasis, as will be discussed in chapter two.  
 
Modeling early onset torsion dystonia 
     Early Onset Torsion Dystonia (EOTD) is a movement disorder characterized by involuntary 
muscle contractions that begins in childhood (Fahn, 1988). There is currently no cure for the 
disease, leaving the young individuals who are diagnosed with it to face a lifetime of 
medications and surgical treatments that sometimes can only partially alleviate the symptoms. 
It is caused by a single glutamic acid deletion in the gene torsinA (torsinAΔE), which is inherited 
in an autosomal dominant manner with reduced penetrance (Bressman et al., 1989; Ozelius et 
al., 1997). 
     TorsinA is a AAA+ ATPase that resides in the ER and nuclear membrane (Hewett et al., 2003; 
Kustedjo et al., 2000). This family of ATPases plays many roles in the cell (Hanson and 
Whiteheart, 2005), including protein remodeling, like the family member HSP104 (Parsell et al., 
1994). This, combined with the fact that torsinA is often found in LB (Shashidharan et al., 2000a; 
Shashidharan et al., 2000b), led to the hypothesis that torsinA may also play a role in protein 
remodeling. Indeed, torsinA can untangle proteins in vitro (Burdette et al., 2010) and reduce 
aggregation of α-syn in H4 neuroglioma cells (McLean et al., 2002). TorsinA has also been 
implicated in relieving ER stress (Burdette et al., 2010; Chen et al., 2010) and affects trafficking 
(Hewett et al., 2007; Torres et al., 2004), which all may be linked to its role in protein 
remodeling. Many of these studies have also shown that the EOTD-related glutamic acid 
deletion blocks the function of torsinA.  
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     In chapter three, I describe a model of torsinA function and/or toxicity in S. cerevisiae. 
Unfortunately, these goals were not met, as every assay I attempted failed to demonstrate a 
phenotype of torsinA expression. I hope that as more becomes known about torsinA function, 
especially its post-translational processing, which may require enzymes not conserved in S. 
cerevisiae, that my work can serve as the basis for improving the model and allow S. cerevisiae to 
be utilized to understand torsinA function in a manner similar to its use in studying α-syn.  
 
Concluding remarks 
     It is striking to look back on the success of studying disease-related proteins in S. cerevisiae; 
however, upon closer examination of yeast as a model organism, it should not be surprising. In 
terms of cellular biology, S. cerevisiae is at the pinnacle of combining both ease of genetic 
analysis with conservation to higher eukaryotes at an intracellular level. While this single-celled 
organism may not be able to answer questions about how disease-related proteins affect 
organisms at a level of cell-cell communication or organ function, as it becomes clear that 
understanding the cellular defects associated with disorders helps us decipher the disease 
mechanism, we begin to appreciate the utility of such an elegant model.  
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Abstract  
     Synucleinopathies are a group of neurodegenerative diseases associated with the 
toxicity of alpha synuclein (-syn). -Syn splice isoform expression varies with disease, but 
it is not known how these isoforms affect the protein’s function. Using yeast, we 
investigated two of the most abundant isoforms, which result in deletion of exon four (-
syn4) or exon six (-syn6). -Syn4, missing part of the lipid binding domain, had 
reduced toxicity and membrane binding. -Syn6, missing part of the protein-protein 
interaction domain, also had reduced toxicity but no reduction in membrane binding. When 
expressed at high enough levels to cause toxicity, the splice isoforms generally duplicated 
the biological activities of wild-type -syn, but responded differently to expression sterol 
binding proteins and to chemical inhibitors of sterol synthesis. Our findings suggest that 
the splice variants may be part of a protective response to -syn toxicity. Given the 
prevalence of cholesterol-reducing drugs in modern medicine, the role of these isoforms in 
diverse synucleinopathies warrant further investigation.  
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Introduction 
     Alpha synuclein (-syn) is a small, 14kDa protein associated with progression of 
synucleinopathies, a family of neurodegenerative diseases. These include Parkinson’s 
disease (PD), multiple system atrophy, and dementia with Lewy bodies (Lee and 
Trojanowski, 2006), which are characterized by the degeneration of different neuronal cell 
types. The accumulation of misfolded -syn is a hallmark of all of these diseases. Moreover, 
increased expression (through -syn by copy number variation or the effects of regulatory 
SNPs) can drive these diseases (Kruger et al., 1998; Mizuta et al., 2006; Polymeropoulos et 
al., 1997; Zarranz et al., 2004). Indeed, many laboratories now model synucleinopathies by 
overexpressing -syn (Feany and Bender, 2000; Lakso et al., 2003; Masliah et al., 2000; 
Outeiro and Lindquist, 2003).   
    The structural properties of -syn provide insight into its biology. Its N-terminus is 
comprised of seven imperfect repeats that fold into amphipathic helices in the presence of 
lipids, allowing -syn to interact with membranes (Davidson et al., 1998). -Syn can also 
form toxic multimers, a property dependent on amino acids 71-82 (Giasson et al., 2001). 
Finally, the protein contains an unstructured C-terminal tail important for various protein-
protein interactions (Eliezer et al., 2001). These basic biophysical properties generally 
affect -syn functionality, allowing much simpler cell types, such as yeast, to be used in 
modeling -syn-induced cellular pathologies.  
     Studying the cell biology of -syn in Saccharomyces cerevisiae affords multiple 
advantages (Khurana and Lindquist, 2010). Yeast share fundamental eukaryotic cell 
biology with higher organisms, including vesicular trafficking, protein homeostasis, 
mitochondria, peroxisomes, autophagy and other functions of direct relevance to disease. 
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Moreover, yeast provide an unparalleled genetic toolbox, enabling both detailed 
hypothesis-driven analyses and unbiased screen-based discovery.  
    When -syn is expressed at low levels in yeast, it localizes to the plasma membrane, 
highlighting its lipophilic nature. In both yeast and neurons, -syn associates with lipid 
rafts, suggesting that -syn displays similar lipid binding preferences in both cell types 
(Fortin et al., 2004; Zabrocki et al., 2008). At higher expression levels, -syn foci form 
(Outeiro and Lindquist, 2003). Higher expression also elicits a number of cellular defects, 
including slowed growth, disrupted vesicle trafficking, lipid droplet accumulation, and 
mitochondrial dysfunction (Cooper et al., 2006; Outeiro and Lindquist, 2003). Importantly, 
these phenotypes have been verified in higher organism models of synucleinopathies. 
Studies in yeast also established a previously unknown link between -syn and a second 
parkinsonism-associated protein, ATP13A2, and connected both proteins to manganese 
homeostasis (Gitler et al., 2009). Further, high-throughput screens identified compounds 
that rescue yeast and neuronal cells not only from -syn-induced toxicity but also from 
mitochondrial poisons associated with PD (Su et al., 2010). Clearly, yeast models can 
provide insights on -syn function that are directly relevant to neuropathology. 
     Here we use a yeast model to investigate naturally-occurring splice isoforms of -syn. 
Full length -syn (-synFL) contains seven exons (Beyer and Ariza, 2012; Xia et al., 2001). 
(Note that exon numbering has recently been adjusted, due to discovery of a new exon in 
the 5’-untranslated region; Beyer and Ariza, 2012.). Exons one and two, as well as part of 
exon three, constitute the 5’-untranslated region of the mRNA. The remainder of exon 
three, as well as exon four and part of exon five comprise the N-terminal region of the 
protein, while the rest of exon five, as well as exons six and seven, create the C-terminal tail 
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of the protein. Both exon four and exon six are subject to alternative splicing, creating -
syn4 and -syn6, respectively. These variants are differentially expressed in various 
synucleinopathies (Beyer et al., 2008; Campion et al., 1995; McLean et al.; Ueda et al., 1994) 
and recent work tied PD risk factors to increased splicing of exon six (Kalivendi et al., 2009; 
McCarthy et al., 2010). Whether this change in splicing contributes to pathology, is part of a 
protective mechanism, or is functionally inconsequential is unknown.  
     Here, we compared the biological effects of -syn4 and -syn6 with -synFL. We 
characterized differences in the localization of each isoform and their relative toxicities. 
Testing the effects of 75 genes that modify the toxicity of -synFL against the splice 
isoforms, we uncovered a differential response to the oxysterol-binding proteins Osh2p 
and Osh3p. This led us to study the sensitivity of -synFL and the splice isoforms to 
perturbations in sterol synthesis.  
 
Results and Discussion 
Splice isoforms of α-syn display different toxicity 
     To investigate how variations in splicing affect the toxicity of -syn we created strains 
that expressed equal copy numbers of -synFL, -syn4, or -syn6 (Figure 2.1a). Genes 
directly encoding these variants were integrated into the HIS3, LEU2, TRP1, and URA3 loci. 
Such transformants can contain multiple tandem integrants, which would confound this 
analysis. Therefore, we designed a PCR-based method to detect single integrants at each 
locus (Figure 2.S1) and generated strains containing single integrations of all isoform at 
each (Figure 2.1b). This allowed a precisely controlled comparison of isoform toxicities. All 
of the genes were driven by the same galactose-inducible promoter so that expression 
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could be induced by shifting cells to galactose containing media. Increasing copy numbers 
increased RNA expression. (Note that due to limiting concentrations of critical regulatory 
factors, mRNA expression does not increase commensurately with gene copy number; 
Figure 2.1c.)  
     Each protein variant accumulated to approximately the same level after galactose induction, 
indicating that the proteins have similar turnover rates (Figure 2.1d). As expected, strains 
carrying four copies (4x) of -synFL displayed strong toxicity. In contrast, 4x -syn6 strains 
showed only marginal toxicity and 4x -syn4 strains grew as well as the GFP control strain 
(Figure 2.2a). Thus, when expressed on their own, the proteins have very different inherent 
capacities to derange cellular homeostasis. 
     The splice isoforms are not expressed in the absence of -synFL in the brain. To assess the 
ability of these isoforms to contribute to the toxicity of -synFL, we constructed strains with 
two copies (2x) of each splice isoform and two copies of -synFL. Strains expressing only 2x -
synFL showed no growth defect, in keeping with the extreme dosage sensitivity previously 
reported for this protein in yeast and in humans (Outeiro and Lindquist, 2003). With this level 
of -synFL expression however, the addition of two copies of either splice isoform was toxic. -
Syn4 enhanced toxicity to a lesser degree than -syn6 (Figure 2.2b). Therefore, while both 
splice isoforms are intrinsically less toxic, they can nevertheless contribute to the toxicity of the 
full-length protein.  
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Figure 2.S1. Diagram showing the primer placement for testing for single integration of 
pRS plasmids.  
Primers were designed to be used regardless of the identity of the inserted gene. Colony PCR 
was used with primer sets A+B, C+D, A+D, and B+C. A+B and C+D would result in a band if there 
was a correct insertion; A+D would result in a band if there was no correct insertion, and B+C 
would result in a band if there were tandem insertions. After this screening, long extension PCR 
was used with primers A+D to confirm the results.  
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Figure 2.1. Creation of strains with equal copy numbers of the α-syn splice isoforms.  
(a) Summary of isoforms tested.  
(b) Real time PCR analysis of DNA levels of splice isoform strains, compared to one copy 
of α-synFL. 1x-4x represents α-syn copy number. n=2, error bars represent standard 
deviation.  
(c) Real time PCR analysis of RNA levels from induction of α-synFL strains. 1x-4x 
represents α-syn copy number.  Levels were normalized to PGK1, and compared to 
one copy of α-synFL. n=3, error bars represent standard deviation. 
(d) Western blot analysis of strains with 1x-4x copies of splice isoforms. PGK1 = loading 
control. 
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Splice isoforms of α-syn display different localization 
     As previously reported, when first induced, -synFL localizes to the plasma membrane. 
As it accumulates to toxic levels, it begins to form foci, first around the periphery of the cell 
and then extending into the interior (Gitler et al., 2008). In the 4x strains, after six hours of 
induction, -synFL was observed at both locations (Figure 2.2c). -Syn4 lacks a portion of 
the N-terminal amphipathic helix required for lipid binding and localized less efficiently to 
the plasma membrane. -Syn6, which has the lipid binding domain intact, was primarily 
localized to the plasma membrane (Figure 2.2c). At this level of expression, -syn4 and -
syn6 rarely formed foci. These results confirm the previously reported role of the N-
terminal lipid binding-domain of -syn in foci formation (Volles and Lansbury, 2007) and 
implicate the C-terminal region of -syn as well. -SynFL foci are the sites of accumulation 
of blocked vesicles (Gitler et al., 2008). Thus, this result suggest the C-terminal 
protein::protein interaction domain (Auluck et al., 2010), plays an important role in 
blocking vesicular trafficking. 
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Figure 2.2. α-Syn splice isoforms elicit different toxicities and localization when 
expressed at the same level in Saccharomyces cerevisiae. 
(a) Spot assay of -syn-expressing strains with four copies of the indicated isoforms. 
Glc = glucose. 
(b) Spot assay of strains co-expressing -synFL and the splice isoforms. Glc = glucose. 
(c) Microscopy reveals differential localization of splice isoforms. Fluorescent 
microscopy of 4x splice isoform strains. Scale bar = 5 μM. 
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Tandem plasmid integration results in strains with similar levels of toxicity 
     We have previously described several cellular processes that are affected by -syn in 
yeast, and have determined the effect of most genes in the genome on -syn toxicity 
(Cooper et al., 2006; Outeiro and Lindquist, 2003). Taking full advantage of yeast genetics 
to investigate functional differences between the splice isoforms required strains with 
similar levels of toxicity (Figure 2.3a). To create such strains, we isolated transformants 
with different numbers of tandem plasmid integrations, selecting those with similar levels 
of toxicity (Figure 2.3 b and c). 
     In these strains, -synFL showed the expected localization pattern, forming small foci 
around the perimeter of the cells and larger foci in the cytoplasm (Figure 2.3d). -Syn4 
and -syn6 also formed foci. However, -syn4 still showed high levels of cytoplasmic 
localization.  
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Figure 2.3. Higher levels of α-syn splice isoform expression leads to higher toxicity and 
foci formation. 
(a) Spot assay of α-syn-expressing strains with different numbers of integrated copies 
but demonstrating equal levels of toxicity. IntTox is a previously created strain 
expressing α-synFL-YFP that was used in a high-throughput overexpression screen. 
Glc = glucose. 
(b) Quantification of the number of α-syn copies inserted into the multi-copy strains by 
real time PCR in comparison to the 1x α-synFL strain. n=2, error bars represent 
standard deviation. 
(c)  Western blot analysis of α-syn splice isoforms in the same multi-copy strains shown 
in (a). PGK1 = loading control. 
(d) Fluorescence microscopy of the same strains as shown in (a) expressing higher 
levels of α-syn. Scalebar = 5 μM. 
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Isoforms of -syn block secretion 
     One of the earliest toxicities associated with -syn expression is a block in secretory 
vesicle trafficking (Cooper et al., 2006). To assess if all splice isoforms could inhibit 
secretion, we used a simple halo assay for mating factor secretion. Cells of one mating type 
are spotted onto a lawn of the other, and the halos of growth arrest provide a qualitative 
measure of mating factor secretion. When tested on glucose plates, no -syn was expressed 
and halos were roughly equal size. In contrast, when spotted on inducing galactose plates, 
strains expressing similarly toxic levels of all three -syn splice isoforms showed similarly 
reduced zones of inhibition. This suggested that all three variants are capable of inhibiting 
secretion (Figure 2.4a). Importantly, this phenotype was not a simple generic affect of 
expressing a toxic protein; toxic levels of the Alzheimer’s disease-related peptide Aβ 
(Treusch et al., 2011) did not significantly affect trafficking.  
     We next asked if the foci formed by the splice isoforms represent -syn-blocked clumps 
of secretory vesicles, as is the case for -synFL (Gitler et al., 2008). This phenotype can be 
probed by assaying colocalization of -syn and secretory pathway proteins, such as Vps21p 
(Gitler et al., 2008). Indeed, colocalization was observed between Vps21p and -synFL, as 
well as -syn4 and -syn6 (Figure 2.4b). In contrast, clatherin heavy chain protein 
Chc1p which is associated with endocytic vesicles did not show colocalization with any of 
the -syn isoforms (Figure 2.S2a). This suggested that all three isoforms of -syn result in 
accumulation of secretory vesicle clusters.  
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Figure 2.4. Splice isoforms elicit toxicity by similar, but not identical, mechanisms. 
(a) Halo assays to test the secretion capacities of α-syn-expressing cells. Mat alpha cells 
were spotted on a lawn of bar1 mat a cells and allowed to grow for two days. The 
zone of clearance surrounding the spot represents growth inhibition by secretion of 
alpha factor. Yeast expressing Aβ serve as a control. Gal = galactose, Glc = glucose.  
(b) Fluorescent microscopy of cells expressing α-syn isoforms, tagged with GFP, and 
mKate-Vps21p. Scalebar = 2 μM.  
(c) Relative growth of α-synFL-expressing strains transformed with genetic modifiers 
of toxicity compared to α-synΔ4- (red) or α-synΔ6- (blue) expressing strains. Each 
point represents the relative growth of the strain transformed with one genetic 
modifier. As is common in high throughput screens, some hits do not repeat upon 
respotting. All hits shown here repeated with the exception of YBR030W. 
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Figure 2.S2. Fluorescent microscopy of  -syn colocalization.  
(a) Fluorescent microscopy of -syn-GFP-expressing cells in addition to an empty vector or 
mKate-Chc1p. Scale bar = 2 μM. 
(b) Fluorescent microscopy showing colocalization of -syn-GFP and mKate-Vps21p. Scale 
bar = 2 μM. 
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α-Syn splice isoforms show differential response to OSH2 and OSH3 overexpression  
     To more thoroughly investigate the mechanisms by which the splice isoforms induce 
toxicity, we tested all 75 of the genes that were identified in an earlier screen as 
suppressors or enhancers of -synFL-induced toxicity (Cooper et al., 2006). Each gene was 
tested in each strain at least three times to ensure the results were reproducible (Figure 
2.S3).  
     Strikingly, most of the genes tested affected each of the splice isoforms in the same direction 
and to the same extent as -synFL (Figure 2.4c). In congruence with the above results, all of the 
trafficking-related modifiers similarly affected -synFL, -syn4, and -syn6. However, a 
small number of genes modified the toxicity of the two splice variants in a manner distinct from 
-synFL. These effects were confirmed in individual spotting assays. Pho80p, a cyclin that 
monitors stress due to nutrient starvation, enhances -syn6 toxicity while suppressing -
synFL and -syn4 toxicity. Furthermore, Osh2p and Osh3p suppressed toxicity of the -synFL-
expressing strain but enhanced toxicity of -syn4 and -syn6.  
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Figure 2.S3. High-throughput transformation of splice isoforms with genetic modifiers of 
α-syn-induced toxicity produced reproducible results.  
Each spot on each graph represents the rate of growth of one splice isoform of α-syn strain 
transformed with one genetic modifier on two separate trials.  
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α-SynFL and α-synΔ6, but not α-synΔ4, elicit sensitivity to simvastatin and fluconazole 
     Given the role of Osh2p and Osh3p in mediating cellular sterol localization (Schulz and Prinz, 
2007) and recent, somewhat perplexing connections between PD and cholesterol (Huang et al., 
2008; Pahan et al., 2009; Wolozin et al., 2007) we focused on the relationship between sterols 
and -syn toxicity. S. cerevisiae cells utilize ergosterol, rather than cholesterol as their principle 
sterol, but the two molecules are very similar and serve the same function in maintaining the 
correct fluidity of the plasma membrane. -SynFL-expressing yeast were sensitive to treatment 
with statins, which inhibit of the enzyme HMG-CoA reductase, a rate-limiting step in the 
production of sterols in both yeast and humans (Yeger-Lotem et al., 2009). Therefore, we asked 
if cells expressing the splice isoforms of -syn were similarly sensitive to treatment with 
simvastatin, a commonly prescribed statin in man.  
     -synFL and -syn6 expression caused sensitivity to doses of simvastatin that were not 
toxic to control cells; -syn4 did not (Figure 2.5a). Statins inhibit a very early step in sterol 
production and disrupt multiple pathways related to -syn-induced phenotypes, such as the 
production of quinones, dolichol formation, and prenylation. Therefore, to focus more precisely 
on sterol metabolism, we took advantage of a more specific inhibitor. Fluconazole inhibits 14-
demethylase, an enzyme specific to a late step in ergosterol synthesis. Yeast treated with 
fluconazole accumulate a modified sterol, 14-methyl-3,6-diol, which increases membrane 
fluidity (Abe et al., 2009). We treated -syn splice isoform-expressing yeast with concentrations 
of fluconazole that were not toxic to control cells. Again, -synFL and -syn6 were sensitive to 
fluconazole treatment, while -syn4-expressing cells were not (Figure 2.5a). Therefore, a shift  
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Figure 5. α-Syn splice isoforms show differential sensitivity to changes in ergosterol 
levels. 
(a) Spot assay comparing the sensitivities of strains expressing α-syn splice isoforms to 
simvastatin and fluconazole. Glc = glucose. 
(b) Fluorescent microscopy showing partial colocalization of α-syn-GFP and ergosterol 
(false-colored red). FL = α-synFL, Δ4 = α-synΔ4, Δ6 = α-synΔ6. Scalebar = 2 μM. 
(c) Fluorescence microscopy showing the impact of fluconazole treatment on α-syn foci 
formation. Scalebar = 5 μM. 
(d) Percent of cells with large α-syn foci after four hours of induction. n=3, error bars 
represent standard deviation, * = p<0.05 in a paired t-test.  
(e) Fluorescence microscopy showing the impact of fluconazole treatment on α-syn 
localization. Fields lacking cells with foci were chosen to highlight membrane 
binding. Scalebar = 2 μM. 
(f) Model suggesting the mechanism by which fluconazole enhances α-synFL and α-
synΔ6 toxicity.  
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in sterol balance, and an increase in membrane fluidity, sensitizes cells to -syn, but the spliced 
isoform -syn4 resists this effect. 
 
α-Syn-induced sensitivity to fluconazole can be attributed to an increased trafficking block 
     Since -synFL foci represented lipid-rich, vesicular clusters blocked in trafficking by -synFL 
protein, we asked if these clusters were enriched in sterols by staining with filipin, a fluorescent 
probe that binds sterols. In vector control cells, filipin displayed canonical staining of the plasma 
membrane, which has the highest sterol content in the cell (Zinser et al., 1991) (Figure 2.5b). In 
strains expressing all three isoforms of -syn, filipin colocalized with to both the plasma 
membrane and to large intracellular -syn foci (Figure 2.5b). Intriguingly, in many cases some 
foci stained with filipin and others did not. This might simply be a technical artifact, but it 
suggests heterogeneity in the membrane sterol content of vesicles trapped at these foci. In cells 
that had higher concentrations of filipin localized to -syn foci, we saw less filipin staining at the 
plasma membrane. Therefore, -syn causes a redistribution of endogenous sterols. One 
mechanism by which sterols arrives at the plasma membrane is by transport through the 
secretory pathway (Schulz and Prinz, 2007). Since -syn expression blocks vesicular trafficking, 
sterol transport is also blocked by -syn expression. 
     How might fluconazole treatment affect -syn localization? Incubation with fluconazole 
elicited a striking relocalization of -synFL and -syn6 but not -syn4 (Figure 2.5c). -
SynFL- and -syn6-expressing cells treated with fluconazole were much more likely to form 
foci, even at a time point in which untreated cells show few foci (Figure 2.5d). These foci 
colocalize with Vps21p, a second secretory vesicle marker, suggesting that these foci are all -
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syn decorating clumps of secretory vesicles (Gitler et al., 2008) (Figure 2.S2b). Focusing on cells 
without significant foci, it is also clear that, for -synFL and -syn6, some of the protein 
redistributed to the cytoplasm (Figure 2.5e). This suggests that reductions in the plasma 
membrane sterol content disrupt plasma membrane binding of -synFL and -syn6, but not 
-syn4. This might be due to a specific failure of -syn to bind 14-methyl-3,6-diol or, more 
broadly, to the impact of fluconazole on membrane fluidity (Abe et al., 2009). -Syn4 binds 
membranes more weakly and does not respond to fluconazole treatment, suggesting a role for 
exon four in sterol-mediated membrane binding.  
     This data also suggests one mechanism by which changes in membrane sterol content affect 
-syn toxicity. In yeast, the plasma membrane has the highest ratio of ergosterol:phospholipids 
(Zinser et al., 1991) and, therefore, simvastatin and fluconazole treatments most strongly affect 
the dynamics of -syn interactions with the plasma membrane. -Syn induces toxicity not at the 
plasma membrane, but instead in the secretory pathway (Cooper et al., 2006). Consequently, 
when -syn is expressed at nontoxic levels, the plasma membrane may serve as a reservoir for 
the protein, reducing -synFL and -syn6 interaction with secretory vesicles. (-Syn4, which 
has a lower affinity for membranes overall is less affected.) Depletion of sterols from the plasma 
membrane would liberate -syn (either due to reduced sterol binding or changes in membrane 
fluidity). This would afford a greater opportunity for -syn to interact in a toxic manner with 
vesicles in the secretory pathway (Figure 2.5f).  
     Both -syn4 and -syn6 respond differently to OSH2 and OSH3 overexpression than -
synFL, yet a differential response to fluconazole is only seen by -syn4. Therefore, the 
mechanism for these phenotypes must be disparate. At present the reason for this disparity 
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remains unclear. OSH2 and OSH3 belong to a large family of conserved oxysterol-binding 
proteins with overlapping functions in membrane sterol relocalization that remain to be 
deciphered, both yeast and mammalian cells. Recent work implicates Osh3p in regulating lipid 
concentration at ER/plasma membrane contact sites (Stefan et al., 2011). It is tempting to 
speculate that α-syn is blocking transport between these two organelles and that reorganization 
of the membranes by OSH proteins impacts the binding or functionality of α-syn. This change in 
membrane architecture may allow the splice isoforms to differentially interact with the 
membrane and impart toxicity. The mechanisms remain opaque at present but -syn may 
provide a useful to in disentangling OSH protein functions. 
     Here we have shown that the splice isoforms of -syn exhibit different toxicities and 
membrane binding properties in vivo. Furthermore, these toxicities change in response to 
alterations in intracellular sterol levels. Our work benefited greatly from the genetic 
toolbox available for yeast. Such investigations are far more difficult in neurons but, given 
the current state of confusion about the ties between cholesterol and synucleinopathies 
(Huang et al., 2008; Pahan et al., 2009; Wolozin et al., 2007), the effort seems warranted. 
Since statins are one of the most heavily prescribed drugs in the developed world, 
determining their effects on -syn dynamics, and the role of -syn splice isoforms on those 
dynamics, would seem an imperative for development of the best possible therapeutic 
strategies for treating patients with these diseases.  
 
Materials and Methods 
Materials 
     Simvastatin was obtained from Sigma-Aldrich. Fluconazole was obtained from VWR. 
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Yeast strains and growth conditions 
     All experiments were performed in the W303 yeast background, unless otherwise noted. The 
secretion assays utilized a bar1 mutant strain, MATa bar1 leu2 ura3 trp1 his2 ade1, which was a 
kind gift from the Fink lab. The standard lithium acetate transformation protocol was used for 
all yeast transformations (Gietz et al., 1992; Gietz et al., 1995). To select for single integrants, 
about 50 ng of cut plasmid DNA was used in the transformation. This resulted in a mix of single 
and tandem integrants. To select for tandem integrants, about 500 ng of cut plasmid DNA was 
used in the transformation.  
     Synthetic media included 0.67% yeast nitrogen base without amino acids (Fischer Scientific), 
supplemented with amino acids as needed (MP Biomedicals) and 2% sugar. YP media included 
1% yeast extract, 2% peptone, 2% glucose adjusted to pH 7.0, and 2% sugar. Plates included 2% 
agar.  
     For galactose induction, unless otherwise noted, cells were grown to log phase for 6-8 hours 
in synthetic media containing glucose before being diluted into synthetic media containing 
raffinose for overnight growth. Log phase cells were then diluted into synthetic media 
containing galactose for induction. Unless otherwise specified, cells were induced for six hours.  
 
Plasmid construction 
     α-Syn splice isoforms were generated using overlap extension PCR with Pfu Turbo (Agilent 
Technologies). A seventh exon of α-syn was only recently found. Therefore, in many previous 
works, α-synΔ4 is refered to as α-syn lacking exon 3 or α-syn126 while α-synΔ6 is referred to as 
α-syn lacking exon 5 or α-syn112 (Beyer and Ariza, 2012). The second round of PCR also added 
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the sequences required for subcloning via BP reaction into pDONR221 (Invitrogen) (Hartley et 
al., 2000; Walhout et al., 2000). The resulting entry clone was then utilized in an LR reaction to 
move the insert to a variety of necessary entry vectors, all from the pAG series (Alberti et al., 
2007).  
     For colocalization studies, PCR with Pfu Turbo was used to add XhoI and PstI sites to α-synFL. 
This was digested and subcloned into the Gateway® TagRFP-AS-N entry clone (Evrogen), 
which was then used in LR reactions to move the insert into one of the pAG series vectors.  
     For screening previously established genetic modifiers of α-syn-induced toxicity, the hits 
were cherry-picked from the Yeast FLEXGene collection (Hu et al., 2007). Any gene used in low-
throughput was cherry-picked from the original library and sequence-verified. If required in a 
different vector backbone, the gene was moved to pDONR221 by BP reaction, then to a vector of 
the pAG series by LR reaction. mKate-CHC1 and mKate-VPS21 were constructed with the same 
protocol and transformed into pRS-GPD-mKate-ccdB.  
 
Single insertion PCR analysis 
     Colony PCR was used to screen all created strains for those with a single insertion in the 
correct locus (see Figure S1 A). Primers used for this analysis were:                       
HIS3-TRP1-URA3-C (GGCTTAACTATGCGGCATCAGAGC), HIS3-A (CGACGCTTTGTCTTCATTCA), 
HIS3-B (CGCATATGATCCGTCGAGT), HIS3-D (ACCACTTGCCACCTATCACC), TRP1-A 
(GCTGACAGGGAAATGGTCAG), TRP1-B (CGATTTCGGCCTATTGGTTA), TRP1-D 
(CCCCCTGCGATGTATATTTT),  URA3-A (AATGTGGCTGTGGTTTCAGG), URA3-B 
(CGTTGGAGTCCACGTTCTTT), URA3-D (GGCGAGGTATTGGATAGTTCC), LEU2-A 
(GGCACAAAGGCAATGAGACT), LEU2-B (CGGCATCAGAGCAGATTGTA), LEU2-C 
82 
 
(TCTGTGCGGTATTTCACACC), LEU2-D (AACGGATCTCCAGATCATCG). Correct strains were 
those that PCR-amplified bands with primers A+B and C+D, but not A+D and B+C. Those that 
were correct by this first screening were analyzed by long extension PCR (Roche).  
 
Real time PCR 
     Genomic DNA was extracted using the YeaStar Genomic DNA Kit (Zymoresearch) or RNA was 
extracted using an RNeasy Mini Kit (Qiagen) and converted to cDNA with a QuantiTect Reverse 
Transcription Kit (Qiagen). Levels of α-syn and PGK1 (control) were then measured using a 
QuantiFast SYBR Green PCR Kit (Qiagen) in triplicate. Primer pairs used for this analysis were: 
α-syn (TGGCTGAGAAGACCAAAGAGC and CTTGCCCAACTGGTCCTTTTTG), PGK1 
(AATCGGTGACTCCATCTTCG and GTGTTGGCATCAGCAGAGAA). 
 
Fluorescent microscopy 
     Cells were induced following standard galactose induction before visualization by fluorescent 
microscopy. Cells were spun down, washed, and resuspended in 1x PBS before being viewed 
with a Plan Apochromat 100x/1.40 NA oil objective lens on a Nikon Eclipse Ti microscopy at 
room temperature. Images were taken with a CoolSNAP HQ camera (Photometrics). Z stacks 
were taken above and below the plane of focus, which were then deconvoluted by using the 3D 
deconvolution algorithm in the NIS-Elements HR software.  
     For localization studies in the presence of fluconazole, cells were induced as outlined above. 
To examine localization changes in the presence of 10 μM fluconazole, the drug was added 
during growth in raffinose and cells were treated overnight before being induced with galactose 
for four hours. DMSO was used as the vehicle. After four hours, cells were imaged as above, and 
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foci were counted from GFP pictures taken of fields chosen in the DIC channel to allow for 
unbiased field selection.  
     For filipin staining, cells were induced as outlined above. Following wash, they were 
resuspended in 4% formaldehyde, diluted from 16% formaldehyde (Ted Pella) in PBS, for 15 
minutes. Following two washes in PBS, cells were stained with 500 μg/mL filipin (Cayman 
Chemical) for 10 minutes in the dark before visualization. Similar results were obtained from 
unfixed cells.  
 
Spotting assays 
     Cells were grown overnight to saturation in synthetic media containing raffinose. Every strain 
was diluted to a starting OD600=1.0 and five-fold serial dilutions were made before spotting on 
inducing (galactose) or non-inducing (glucose) plates.  
 
Western blots 
     Following induction, cells were lysed by bead beating in lysis buffer (10mM HEPES pH 7.5, 10 
mM NaCl, 1.5 mM MgCl2, 20% glycerol, 0.5 mM PMSF, and 1x protease inhibitor (Roche)). The 
lysates were then incubated with 0.5% Tween before spinning to remove beads and debris. 
Protein concentration was quantified using the BCA assay (Pierce Protein Research) then 
normalized. Samples were run on a 10% Bis-Tris Gel (Invitrogen). This was transferred to PDVF 
membrane and blocked with 5% milk in PBS. For protein visualization, either anti-GFP (Roche) 
or anti-PGK1 (Molecular Probes) was used as a primary antibody and a dye-conjugated anti-
mouse IgG (LICOR Biosciences) was used as a secondary antibody. The blot was visualized using 
Odyssey Infrared Imaging System (LICOR Biosciences).  
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Secretion assay 
     Strains were struck onto a YP-glucose plate and grown at 30 degrees overnight. The next day, 
bar1 cells were grown in YP-glucose for 4 hours before diluting to plate a lawn on both YP-
glucose and YP-galactose plates. After drying, the test strains were resuspended in sterile water. 
For uninduced controls, 10 μL of culture diluted to an OD600=1.0 was spotted in the center of 
the YPD plate. For the induced plates on YP-galactose, an OD600=1.0 was used for toxic disease 
model strains, while an OD600=0.04 was used for the vector control to account for their 
different rates of growth. Pictures were taken after two days of growth at 30 degrees.  
 
Screening α-syn enhancers and suppressors 
     A standard lithium acetate transformation protocol was adapted for use with 96-well plates 
(Cooper et al., 2006; Gietz et al., 1992; Gietz et al., 1995). Following transformation, cells were 
grown to saturation in synthetic media with glucose lacking uracil to select for cells that took up 
the plasmid. Once at saturation, they were spotted onto synthetic media plates with either 
glucose or galactose. Following two days of growth, galactose plates were scanned and the 
density of the spot was analyzed using ImageQuant TL. This was repeated for each strain at 
least three times.  
 
Statistics 
All statistical analysis was performed using the Student’s t-test, with the exception of goodness 
of fit analysis where a linear regression was used to determine R squared.  
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Abstract 
     Early-onset torsion dystonia is a severe, life-long disease that leads to loss of motor control 
and involuntary muscle contractions. While the molecular etiology of the disease is not fully 
understood, a mutation in an AAA+ ATPase, torsinA, has been linked to disease onset. Previous 
work on torsinA has shown that it localizes to the endoplasmic reticulum, where there is 
evidence that it plays roles in protein trafficking, and potentially also protein folding. Given the 
high level of evolutionary conservation among proteins involved in these processes, as well as 
the previous successes achieved in examining other proteins involved in complex human 
diseases in yeast, we hypothesized that Saccharomyces cerevisiae might represent a useful 
model system for studying torsinA function and the effects of its mutants. Since torsinA is 
proposed to function in protein homeostasis, we tested cells for their ability to respond to 
various stressors, using a fluorescent reporter to measure the unfolded protein response, as 
well as their rate of protein secretion. TorsinA did not impact these processes, even after co-
expression of its recently identified interacting partner, printor. In light of these findings, we 
propose that yeast may lack an additional cofactor necessary for torsinA function or proteins 
required for essential post-translational modifications of torsinA. Alternatively, torsinA may not 
function in endoplasmic reticulum protein homeostasis. The strains and assays we describe 
may provide useful tools for identifying and investigating these possibilities and are freely 
available. 
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Introduction  
     A glutamic acid deletion (ΔE) in torsinA causes early-onset torsion dystonia, a devastating 
autosomal dominant neurofunctional disease that impacts patients as children or young adults 
and has no cure (Bressman et al., 1994). The torsinA protein carries a signal sequence in its N-
terminus that localizes the protein to the contiguous lumen of the endoplasmic reticulum (ER) 
and nuclear membrane (Giles et al., 2009; Hewett et al., 2003; Kustedjo et al., 2000). C-terminal 
to this is a hydrophobic region that allows torsinA to interact with membranes (Liu et al., 2003). 
The remainder of the protein encompasses an AAA+ ATPase domain, which includes the site of 
the dystonia-associated mutation (Ozelius et al., 1997).  
     While AAA+ ATPase domains have been ascribed diverse functions, many are involved in 
protein remodeling (Hanson and Whiteheart, 2005). Yeast have AAA+ ATPases that participate 
in protein folding, such as HSP104 (Parsell et al., 1994), but none are homologs of torsinA. 
However, there is precedent for successfully studying AAA+ ATPases in heterologous 
environments, as HSP104 has been shown to function in neurons, which lack an HSP104 
homolog (Perrin et al., 2007). 
     TorsinA acts in protein trafficking and the dystonia-associated mutation in torsinA disrupts 
this process (Hewett et al., 2007; Torres et al., 2004). Due to the homology between torsinA and 
the Hsp100 family, it was hypothesized that torsinA may function as a chaperone. Indeed, 
recent work has shown that torsinA can untangle protein aggregates in vitro and rescue both 
nematodes and mouse embryonic fibroblasts from ER stress (Burdette et al., 2010; Chen et al., 
2010). However, work in PC6.3 cells showed that while the ER stressor dithiothreitol (DTT) 
induces post-translational modification of torsinA in rat PC6.3 cells, torsinA cannot rescue ER 
stress or protein aggregation of polyglutamine (Gordon et al., 2011). This discrepancy may arise 
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from differences between cell lines. The latter paper was the only one to use a neuronal cell line, 
which may be the most representative of the cell type impacted by dystonia. TorsinA is present 
in Lewy bodies (LB), the proteinaceous aggregates that are a hallmark of Parkinson’s disease 
(PD) (Shashidharan et al., 2000a; Shashidharan et al., 2000b). TorsinA is able to reduce the 
aggregation of a principal component of LB, alpha-synuclein (α-syn), in H4 neuroglioma cells, 
and lessen the neuronal death caused by α-syn expression in nematodes (Cao et al., 2005; 
McLean et al., 2002). This aspect of torsinA biology is not completely understood since torsinA 
is localized to the ER (Hewett et al., 2003) and LB and α-syn exist in the cytoplasm (McLean et 
al., 2002; Shashidharan et al., 2000a), but could potentially be explained by ER associated 
protein degradation (ERAD) (Giles et al., 2008); although more work is needed on this topic. 
Hence, while data suggest certain cellular functions for torsinA, the details of this role in protein 
homeostasis is far from understood and it is unclear how the disease-associated mutation of 
torsinA interferes with its proposed chaperone function. 
     Many studies have revealed the utility of modeling complex biology in the yeast 
Saccharomyces cerevisiae. Yeast have an unrivaled genetic toolbox for both hypothesis-based 
and unbiased high-throughput analyses (Khurana and Lindquist). Furthermore, yeast have been 
vital in understanding processes involved in protein homeostasis, including the unfolded 
protein response (UPR) and the role of chaperones (Lindquist and Craig, 1988; Mori, 2009). 
More recently, yeast have been utilized to model the cell biology of neurodegenerative diseases, 
including polyglutamine (polyQ) diseases (e.g., Huntington’s disease) (Krobitsch and Lindquist, 
2000), synucleinopathies (e.g., PD) (Outeiro and Lindquist, 2003), and Alzheimer’s disease 
(Bharadwaj et al., 2008; Caine et al., 2007; Middendorp et al., 2004). 
     Studies of this nature concerning the cell-biological role of α-syn have been particularly 
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successful. α-Syn elicits toxicity when expressed in yeast, as well as cellular phenotypes 
reminiscent of those observed in PD patients (Outeiro and Lindquist, 2003). From high-
throughput screens, our lab and others began to elucidate how α-syn expression alters normal 
cellular functions. One such screen assayed the consequences of overexpressing individual yeast 
genes on α-syn-induced toxicity; this revealed conserved cellular processes perturbed by α-syn 
expression in yeast and higher eukaryotes, including ER-to-Golgi trafficking, and established a 
link between α-syn and PARK9, a gene previously associated with PD by genetic analyses, but 
not known to be functionally tied to α-syn (Cooper et al., 2006; Gitler et al., 2009; Yeger-Lotem 
et al., 2009). A second yeast-based screen discovered chemical compounds capable of rescuing 
not only α-syn-induced toxicity in neurons, but also toxicity triggered by the drug rotenone, 
which represents an independent model for PD (Su et al., 2010).  
     Motivated by the success of these prior yeast models, here we attempt to investigate the 
cellular effects of torsinA expression in Saccharomyces cerevisiae. Upon expression of torsinA in 
yeast, we find that torsinA does not detectably impact protein folding and secretion under the 
many conditions that we have tested. Although we would not normally report negative results, 
we do so for several reasons. First, due to the past success of modeling complex diseases in 
yeast, we foresee others attempting similar studies and hope that this work will serve as a 
starting point for their analyses. Secondly, it is possible that our failure to detect significant 
changes upon torsinA expression may be due to missing cofactors, improper protein processing, 
or subcellular environmental differences between yeast and higher eukaryotes. As these topics 
are understood in greater detail, this model may come to serve as a useful tool for the discovery 
of torsinA function and torsinA-interacting partners. For these reasons, all plasmids created in 
this study will be made freely available from Addgene.  
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Results 
Expression of torsinA in the yeast ER requires a yeast ER localization signal 
     TorsinA is a resident ER protein (Hewett et al., 2003; Kustedjo et al., 2000). However, 
expression of full-length torsinA in yeast, driven by a high-expression galactose-inducible 
promoter, resulted in the formation of large cytoplasmic aggregates (data not shown). Since we 
were interested in studying the ability of torsinA to act specifically in the ER, we wished to 
localize the protein to this cellular compartment. To accomplish this, we replaced the 
endogenous ER localization sequence of torsinA (Giles et al., 2009) with the localization 
sequence of the yeast ER-resident protein, Kar2p (Figure 3.1a) (Tokunaga et al., 1992). 
Importantly, in this construct, only the portion of torsinA that has been shown previously to be 
cleaved following ER localization was replaced (Hewett et al., 2003; Liu et al., 2003), leaving all 
functional domains of the final protein intact. This caused torsinA to localize to the ER, as 
visualized by C-terminal green fluorescent protein (GFP) tagging of torsinA (Figure 3.1B). Even 
in the ER, the protein still aggregated significantly when expressed from the galactose-inducible 
promoter (data not shown). Therefore, the expression level of torsinA was decreased by using 
the MET25 promoter. For all experiments other than microscopy, the GFP tag was replaced with 
an HDEL (ER retention) motif to ensure that any torsinA mistakenly trafficked to the Golgi 
apparatus would be returned to the ER (Pelham, 1989).  
     While the data presented below exclusively utilize this form of torsinA, in which the 
endogenous localization sequence was replaced with that from KAR2, pilot studies were 
performed using two other fusion constructs. The first attached the KAR2 localization sequence 
to full-length torsinA and the second utilized torsinA lacking both the endogenous signal 
sequence and hydrophobic domain. Both of these forms of the protein elicited similar results to 
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those outlined below (data not shown).  
     Multiple isoforms of torsinA were used in these analyses (Figure 3.1a). TorsinAΔE, the 
mutation associated with early-onset torsion dystonia, lacks a glutamic acid at position 302 or 
303 (Ozelius et al., 1997). It was hypothesized that this form of the protein may lose torsinA-
associated activity, as it has previously been shown that torsinAΔE acts by a dominant-negative 
mechanism (Torres et al., 2004). Furthermore, the ATPase activity of torsinA is required for its 
chaperone function (Chen et al., 2010). Therefore, control constructs were created by inserting 
two previously characterized mutations in the AAA+ domain into both torsinA and torsinAΔE - 
K108A or E171Q, which inactivate ATP binding and hydrolysis, respectively (Naismith et al., 
2004). 
     KAR2-tagged torsinA displayed predominantly ER-localized, non-aggregated expression, 
suggesting the signal sequence was sufficient for relocalization (Figure 3.1b) (Ronicke et al., 
1997). Some cytoplasmic foci were still observed and low-level GFP was also seen in the vacuole 
(arrowhead points to one example), suggesting that some of the protein was being degraded 
(Figure 3.1b). We performed a spotting assay to assess the impact of torsinA expression on the 
yeast growth rate. None of the forms of torsinA examined impaired or accelerated the rate of 
growth, suggesting that torsinA expression did not significantly perturb any yeast cellular 
processes essential for growth (Figure 3.1c). Importantly, torsinAΔE did not diminish the 
growth rate of yeast, suggesting that the mutation does not act by a dominant, gain of function 
mechanism to impede cell viability in our model.  
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Figure 3.1. TorsinA can be expressed in the endoplasmic reticulum of yeast. 
(a) Diagram of constructs created for this work (upper panel) and summary of the different 
forms of torsinA used in these experiments (lower panel). TorsinA was localized to the 
endoplasmic reticulum (ER) using the signal sequence of the endogenous yeast protein KAR2 
and an HDEL sequence.  
(b) Microscopy of yeast strains used. TorsinA was localized to the contiguous lumen of the 
nuclear envelope and ER. Some signal was also seen in the vacuole (arrow head), suggesting a 
portion of the protein was degraded. A representative frame is shown for each strain. Scale bar 
= 2 μM. 
(c) Growth of torsinA-expressing yeast on plates. Each row is a 5-fold dilution of the 
previous row. Expression of wild type (WT) or mutant torsinA did not impact the growth rate. 
Uninduced plates included 1 mM methionine and induced plates lacked methionine.  
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Expression of torsinA in yeast does not allow for recapitulation of its roles in protein homeostasis 
and trafficking 
     To test if torsinA could function as a chaperone, yeast strains were assayed for ability to 
overcome protein folding perturbations in the presence of wild type (WT) and mutant torsinA. 
To monitor the onset of the UPR, we utilized a previously described reporter that consists of 
GFP driven by four copies of the promoter from a UPR-responsive gene (UPRE), thus allowing 
dose-dependent monitoring of an upregulation in the UPR (Cox et al., 1993; Pollard et al., 1998). 
Each torsinA construct elicited a slight, yet significant, basal increase in the UPR in yeast, as 
compared to an empty vector (Figure 3.2a), likely due to the expression of extra protein 
molecules in the ER. This was not torsinA-specific, since the reporter gene luciferase, when 
expressed in this manner, elicited the same response (data not shown). For this reason, we 
assayed the ability of WT torsinA to modulate the UPR in comparison to mutant forms of the 
protein, hypothesizing that any biologically meaningful effects of torsinA expression should be 
attenuated by the disease-associated mutation and/or the mutations that inactivate ATP 
binding. None of the torsinA isoforms elicited an UPR that was significantly different from the 
others, suggesting that the rise in UPR was not due to mutant torsinA dysfunction (Figure 3.2a).  
     This assay was used to study the ability of torsinA to impinge upon the UPR induced by 
oxidative protein damage in yeast by treating torsinA-expressing cells with DTT. DTT causes 
oxidative ER stress by inhibiting disulfide bond formation, thus eliciting the UPR (Pollard et al., 
1998). Recent work has suggested that a C. elegans homolog of torsinA, ooc-5, can act as a sensor 
of intracellular oxidation, as it contains a disulfide bond important for ATP/ADP binding (Zhu et 
al., 2008). DTT triggered the UPR in our strains; however, none of the torsinA isoforms tested 
lowered the levels of DTT-induced UPR (Figure 3.2a). To ensure that our reporter system was 
98 
 
sensitive to the functions of proteins known to reduce oxidative protein damage, we expressed 
the yeast protein, ero1p. This protein is an oxidase that is necessary for oxidative protein folding 
and can reduce levels of UPR upon stress (Frand and Kaiser, 1998; Pollard et al., 1998). Indeed, 
we observed that it significantly reduced the level of DTT-induced UPR (Figure 3.2a).  
     As a second assay to gauge the ability of torsinA to reduce cellular stress associated with 
oxidative damage in yeast, torsinA was expressed in a strain containing the ero1-1 mutation, 
resulting in a temperature-sensitive ero1p that limits growth at 37°C (Frand and Kaiser, 1998). 
Neither torsinA nor torsinAΔE impacted growth of ero1-1 at this restrictive temperature (Figure 
3.2b).   
     Next, we asked if torsinA could reduce the levels of the UPR induced by sources other than 
oxidative stress in yeast. A constitutively unfolded mutant form of carboxypeptidase Y (CPY*) is 
an ER-associated degradation (ERAD) substrate that can elicit the UPR (Travers et al., 2000). 
Coexpression of any form of torsinA with CPY* had no significant effect on the level of the UPR 
observed (Figure 3.2a). Additionally, pilot studies were performed to test the ability of torsinA 
to reduce the UPR elicited by tunicamycin, a glycoprotein synthesis inhibitor; however, no 
significant differences were observed (data not shown). 
     Multiple studies have documented that torsinA plays a role in vesicular trafficking (Granata et 
al., 2008; Hewett et al., 2007; Torres et al., 2004). Similar to the chaperone system that oversees 
protein folding, secretion is a highly conserved pathway with many proteins displaying 
extensive homology between yeast and higher organisms (Bennett and Scheller, 1993). 
Therefore, we investigated whether torsinA expression altered protein trafficking in yeast. To 
do so, we utilized a previously established assay for secretion that monitors trafficking of the 
endogenous yeast protein invertase to the plasma membrane, where it cleaves sucrose, 
99 
 
  
Figure 3.2. TorsinA does not impact the unfolded protein response or trafficking in yeast. 
(a) A construct containing GFP driven by a unfolded protein response (UPR) sensitive 
promoter (UPRE-GFP) was used to monitor levels of the unfolded protein response (UPR) upon 
stress with 1.5 mM dithiothreitol (DTT) or mutant carboxypeptidase Y (CPY*). ERO1 served as a 
positive control. TorsinA is not able to reduce UPR levels caused by either stressor. Statistical 
analysis was conducted in comparison to the vector control strain with a 1-tailed Student’s t-
test.  * = p<0.05, # = p<0.005, & = p<0.001. N=6 independent trials per sample.  
(b) Growth of ero1-1 in the presence and absence of torsinA at 37°C. Each row is a 5-fold 
dilution of the previous row. TorsinA is not able to rescue the growth defect by the ero1-1 
mutation. Uninduced plates included 1 mM methionine and induced plates lacked methionine.  
(c) Trafficking of invertase, as monitored by halos produced by growth of torsinA-
expressing strains on plates containing bromocresol purple (BCP). TorsinA does not impact the 
rate of secretion.  
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resulting in a local pH change (Nishikawa and Nakano, 1993). This change can then be 
monitored using the pH-sensitive dye bromocresol purple (BCP). Upon spotting torsinA-
expressing strains onto BCP/sucrose plates, no change was observed in the diameter of the halo 
that resulted from this pH change, suggesting that secretion was not impacted by any of the 
torsinA forms (Figure 3.2c).  
     It has also been suggested that torsinA can prevent the progression of aggregate-associated 
neurodegeneration in models of synucleinopathies and polyQ disorders (Cao et al., 2005; 
McLean et al., 2002). Using the previously described yeast model of α-syn-induced toxicity 
(Outeiro and Lindquist, 2003), we asked whether concomitant expression of torsinA and α-syn 
could rescue this phenotype; however, torsinA had no significant impact on the rate of growth 
in conjunction with α-syn expression (Figure 3.3).  
 
  
Figure 3.3. TorsinA cannot rescue α-synuclein-induced toxicity in yeast. 
Assay showing the ability of yeast to grow in the presence or absence of α-synuclein (α-syn) 
with and without torsinA. Each row is a 5-fold dilution of the previous row. TorsinA cannot 
rescue α-syn-induced toxicity.  
 
101 
 
Addition of the torsinA-interacting protein printor is not sufficient to uncover the role of torsinA 
     The above-cited data suggested that torsinA expression in yeast failed to affect any of the 
cellular processes in which this protein has been shown to act in higher eukaryotic cells. We 
hypothesized that this might be attributable to the fact that yeast lack certain essential 
cofactor(s) that are required for torsinA function. Therefore, we reassessed the ability of torsinA 
to function in the above-stated pathways in the presence of the newly-discovered torsinA-
interacting protein, printor (Giles et al., 2009). The association between torsinA and printor was 
discovered through a yeast two-hybrid screen, suggesting that these two proteins could, at a 
minimum, physically interact within a yeast cell. Furthermore, this prior work demonstrated 
that printor selectively binds torsinA lacking ATP, suggesting printor could act as a cofactor of 
torsinA. TorsinA and printor specifically interact in the ER, and not in the nuclear envelope. For 
this reason, printor was localized to the ER using the Kar2 and HDEL localization sequences, as 
described above for torsinA. Co-expression of WT torsinA and printor in yeast failed to elicit 
differential cellular phenotypes upon examination of CPY*- or DTT-induced UPR or invertase 
trafficking (Figure 3.4a & b, respectively). TorsinAΔE and printor elicited a small reduction of 
UPR induction upon co-expression of CPY* (Figure 3.4a). While this reduction was statistically 
significant, it is unlikely to be biologically relevant since torsinAΔE was previously show to be 
inactive. 
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Figure 3.4. Coexpression of torsinA and printor does not uncover a phenotype stemming 
from torsinA expression. 
(a) The UPR of the indicated yeast strains was monitored by flow cytometry to detect 
expression from the UPRE-GFP construct upon stress with CPY* or 1.5 mM DTT. Coexpression 
of printor does not allow WT torsinA to reduce UPR-related stress. A 1-tailed Student’s t-test 
was used to compare relative fluorescence of torsinA strains to the vector control. *=p<0.01. 
N=6 independent trials per each sample.  
(b) The impact of torsinA with and without printor on trafficking of invertase. Cells were 
spotted on plates containing the pH sensitive dye, BCP. Simultaneous expression of torsinA and 
printor does not impact the rate of secretion.  
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Discussion 
     TorsinA has been proposed to function in two highly conserved cellular processes: protein 
folding and protein trafficking. As such, we hypothesized that torsinA expression in yeast would 
impact these pathways. However, we failed to uncover a role for torsinA-mediated control of 
protein folding and secretion in S. cerevisiae. This observation was surprising because other 
protein folding and remodeling factors, such as HSP104, are readily analyzed when 
heterologously expressed in evolutionarily divergent organisms. Moreover torsinA was shown 
to reduce protein aggregation in vitro, and we hypothesized that these effects would also extend 
to our yeast system (Burdette et al., 2010).  
     However, our present findings can be easily reconciled with this previous work. First, the 
above-cited in vitro study utilized torsinA lacking both its signal sequence and its hydrophobic 
domain. Secondly, the in vitro work, in contrast to previous in vivo work in worms with the full-
length torsinA protein(Chen et al., 2010), was unable to uncover a functional difference between 
torsinA and torsinAΔE (Burdette et al., 2010). It is possible that the same cofactors or post-
translational modifications that are necessary to explain the difference between the in vitro and 
in vivo experiments also account for the inability of torsinA to be biologically active in yeast. It is 
also possible that torsinA must be expressed in subcellular locations other than the ER to 
mediate its function, which would not occur in our model due to the presence of the exogenous 
HDEL tag, which was added to increase the level of torsinA retained in the ER. Alternatively, 
there may be some difference in the ER environment of the yeast cells as compared to higher 
eukaryotic cell, which might prohibit or is redundant with torsinA activity.  
     There are a number of other possible explanations for these disparities. While the majority of 
AAA+ ATPases act as protein remoldeing factors, many have quite specific substrates (Hanson 
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and Whiteheart, 2005), and it is possible that yeast lack torsinA’s substrate(s). Furthermore, the 
UPR may serve a broader range of functions in vertebrates than in yeast (Rutkowski and Hegde, 
2010) and torsinA may function in an aspect of UPR signaling not conserved in yeast.  Finally, as 
mentioned above, recent evidence suggests that torsinA may not act in general protein 
homeostasis. Work in neuronal lines has failed to recapitulate the role of torsinA in protein 
folding, which, noteably, was only seen upon overexpression of torsinA in other models (Gordon 
et al., 2011). Furthermore, torsinA has been knocked out in a variety of model organisms, but 
none of these studies have reported a protein homeostasis-related phenotype. This suggests 
that torsinA may serve a different principal function, such as its role in maintaining nuclear 
envelope structure, which has previously been shown to partially explain the neuron-specific 
sensitivity of torsinA mutation (Goodchild et al., 2005).  
     As more is discovered about torsinA function and its interacting proteins through neuronal 
culture or transgenic animals, the work presented here may provide a platform for further 
investigation using yeast.  Furthermore, this yeast model might prove helpful in discovering 
such cofactors, as it could be screened to identify human genes that interact genetically with 
torsinA. For this reason, all of the plasmids created for this project will be made freely available 
through Addgene for distribution to others who are interested in testing these hypotheses. 
While we failed to uncover a phenotype for torsinA expression in yeast, we are optimistic that 
future work can improve this model and make useful steps toward dissecting the function of 
torsinA and the dysfunction associated with its mutant form.  
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Materials and Methods 
Materials 
    Dithiothreitol, tunicamycin, methionine, and bromocresol purple (BCP) were purchased from 
Sigma.  
 
Construction of plasmids 
     Except where noted, standard Gateway cloning methods were used for cloning (Hartley et al., 
2000; Walhout et al., 2000). pDONR221 (Invitrogen) was used as the donor plasmid and the 
pAG series of plasmids (Alberti et al., 2007) were used as destination vectors.  
     TorsinA and torsinAΔE were obtained as a generous donation from Xandra Breakefield. 
Overlap extension PCR (Pogulis et al., 1996) was used to add the KAR2 and HDEL localization 
sequences. These constructs were expressed in pAG416Gal-ccdB or pAG416Gal-ccdB-GFP 
(Alberti et al., 2007). These were then cut with XbaI and XhoI and subcloned into the same sites 
of 416-Met25. Site-directed mutagenesis was used to create K108A and E171Q mutations with 
Pfu Turbo (Stratagene).  
     pRS313-CPY*-HA was a generous gift from Antony Cooper. After sequencing, mutagenic PCR 
was used to create the same mutation in CPY in pDONR221, which was then used in an LR 
reaction to move to pAG413-Gal-ccdB (Alberti et al., 2007).  
     pPW0533, the 304 4xUPRE-GFP reporter, was a generous donation from Peter Walter. 
Following digestion in within the TRP1 gene, it was transformed into W303 to make a stable 
strain with an integrated copy. 
     Printor cDNA was purchased from Kazusa DNA Research Institute (product ID ORK00224) 
(Nagase et al., 2000). Overlap extension PCR (Pogulis et al., 1996) was used to add the Kar2 and 
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HDEL localization sequences and subclone into pDONR221.  
 
Table 3.1. Primers used. 
# Purpose Sequence 
112 Mutagenic PCR TorsinA E171Q GGTCCATCTTCATATTTGATCAAATGGATAAGATGCATGAGGC 
113 Mutagenic PCR TorsinA E171Q GCCTGCATGCATCTTATCCATTTGATCAAATATGAAGATGGACC 
114 Mutagenic PCR TorsinA K108A GGTGGACAGGCACCGGCGCTAATTTCGTCAGCAAGATCATCG 
115 Mutagenic PCR TorsinA K108A CGATGATCTTGCTGACGAAATTAGCGCCGGTGCCTGTCCACC 
121 Overlap extension PCR for KAR2 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACAAAATGTTTTTCA
ACAGACTAAGCGC 
124 Overlap extension PCR for torsinA GGGGACCACTTTGTACAAGAAAGCTGGGTTATCATCGTAGTAATAA
TCTAAC 
126 Overlap extension PCR for torsinA GGGGACCACTTTGTACAAGAAAGCTGGGTTTCACAATTCATCATGA
TCATCGTAGTAATAATC 
138 Overlap extension PCR for torsinA CCCAGGCTGATGGGCTCCACACCTCTAACTAAAACATTGG 
139 Overlap extension PCR for torsinA CCAATGTTTTAGTTAGAGGTGTGGAGCCCATCAGCCTGGG 
140 Mutagenic PCR CPY* CAAGATTTCCACATCGCTAGGGAATCCTACGCCGGCC 
141 Mutagenic PCR CPY* GGCCGGCGTAGGATTCCCTAGCGATGTGGAAATCTTG 
181 Overlap extension PCR for KLHL14 CCAATGTTTTAGTTAGAGGTATGTCCAGATCCGGGGACAGGACCTC
CACC 
182 Overlap extension PCR for KLHL14 GGGTTTTACAATTCATCATGTTTGTTGTATGGTACACAAGAGGGCA
G 
183 Overlap extension PCR for KLHL14 GGGGACCACTTTGTACAAGAAAGCTGGGTTTTACAATTCATCATGT
TTG 
184 Overlap extension PCR for KLHL14 GAAAGCTGGGTTTTTGTTGTATGGTACACAAGAGGGCAG 
185 Overlap extension PCR for KLHL14 GGGGACCACTTTGTACAAGAAAGCTGGGTTTTTGTTG 
 
Yeast strains and growth conditions 
    With the exception of CKY558 (ero1-1 containing strain; generous gift from Chris Kaiser) 
(Frand and Kaiser, 1998), all experiments were done in the W303 genetic background. The 
standard lithium acetate transformation protocol was used for all yeast transformations (Gietz 
et al., 1992; Gietz et al., 1995). Minimal media included 0.67% yeast nitrogen base without 
amino acids (Fischer Scientific), supplemental amino acids (minus those needed as selectable 
markers) (MP Biomedicals), and 2% sugar, with 2% agar included in plates. All liquid growth 
was performed at 30°C with aeration. Except where noted, growth on plates was performed at 
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30°C. For galactose induction (CPY* and α-syn), strains were grown overnight in SRaff and 
diluted into SGal. For methionine induction (torsinA and printor), cells were grown overnight in 
1 mM methionine overnight and diluted into media lacking methionine. 
 
Spotting assays 
     Cells were grown overnight in SRaff plus 1mM methionine. Strains were diluted to OD600=1.0 
and serially diluted five-fold for six total repetitions before spotting on the appropriate agar 
plates.  
 
UPRE induction assays 
    Cells were grown overnight in appropriate media. Strains were diluted to OD600=0.1 in 
inducing media. DTT was used at the indicated concentrations in order to induce a UPR. After 6 
hours of induction, cells were subjected to flow cytometry (Guava PCA-96, Millipore).  
 
Microscopy 
     Cells were grown to log phase in non-inducing media, then moved to inducing media for 5 
hours. Live cells were visualized by using a Zeiss Axiovert 200 microscope. Z-stacks were taken 
and deconvoluted using the nearest neighbor algorithm from the Axiovision software.  
 
BCP trafficking assays 
     Cells were grown overnight in SD with 1 mM methionine media. They were diluted to an 
OD600 = 1.0 and spotted onto BCP plates containing (as measured in weight/volume) 0.67% 
yeast nitrogen base without amino acids (Fischer Scientific), supplemental amino acids (minus 
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those needed as selectable markers) (MP Biomedicals), 2% sugar, 2% agar, 0.0032% BCP, and 
0.5x PBS. Plates were grown for 3 days at 30°C.  
 
Statistics 
     All data are shown as mean ± standard deviation. A 1-tailed Student’s T –test was performed 
for all comparative statistical analysis.  
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Reasons to model human disease in Saccharomyces cerevisiae 
     There are many reasons why the yeast Saccharomyces cerevisiae has become such a popular 
model organism. Importantly, because yeast are eukaryotic, most of these pathways, including 
cell cycle regulation, DNA damage repair, vesicular trafficking, protein processing and secretion, 
mitochondrial function, and lipid biology, are well conserved with higher organisms. Its genome 
is fully sequenced and is 100 times smaller than that of humans. They lack many redundant 
genes found in higher organisms, making it easier to study a phenotype associated with deletion 
of a gene. Furthermore, most S. cerevisiae genes lack introns, making their approximately 6000 
genes much easier to define and characterize. This has facilitated the creation of a vast array of 
yeast-based genetic libraries that can be utilized for high-throughput, unbiased screening, 
ranging from deletion and tagged libraries to collections of overexpression plasmids that 
encompass most of the 6000 genes.  
     Beyond impressive tools for unbiased analyses, S. cerevisiae is a tractable organism for 
biological research for other reasons. They grow quickly and require only inexpensive reagents. 
This allows for large quantities of yeast to be grown, which is especially important for protein-
level analyses. Furthermore, due to the fact that they have robust homologous recombination 
pathways, S. cerevisiae can be easily transformed with plasmids that can either alter 
endogenous genes or introduce novel sequence elements. Finally, since they have been studied 
so extensively, powerful and intricate methods have been developed for studying many 
fundamental biological processes, allowing researchers to deeply probe the specifics of these 
pathways.  These features allow studies in yeast to progress much faster than those in higher 
organisms; experiments that take weeks in yeast would take months to years in mice.  
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    These traits have prompted scientists to turn to S. cerevisiae in order to obtain information on 
some of the most complex biological processes, including work that has important implications 
for human disease. In one study, approximately 25% of a group of human disease genes 
selected from a wide variety of pathways were found to have yeast homologs based on 
sequence alone (Foury, 1997). For genes with yeast homologs, understanding the function of 
the protein in yeast often provides great insight into its function in human cells. One topic that 
has been widely studied in this manner is cancer. Many of the genes that control the yeast cell 
cycle have human homologs relevant for the progression of cancer (Hartwell, 2002). An 
example of this is the role of aneuploidy in cancer (Pfau and Amon, 2012). Healthy cells 
maintain the correct complement of chromosomes through carefully orchestrated events 
during mitosis. In contrast, many cancer cells have some degree of aneuploidy, which can 
occasionally be quite dramatic. Work in yeast unveiled that this aneuploidy results in 
proteotoxic stress and increased sensitivity to inhibitors of protein degradation, which was later 
recapitulated in mammalian cells (Tang et al., 2011; Torres et al., 2007). This information can 
now be applied to developing therapeutic strategies for cancer (Pfau and Amon, 2012; 
Thompson et al., 2010)  
     Studies in yeast have aided in understanding ties between DNA repair and cancer 
progression as well. For example, it is known that simple sequence repeats are genetically 
unstable, especially in the background of other mutations often found in cancer cells; however, 
the underlying basis for this instability was unknown. Using yeast to discover genes involved in 
the process of DNA repair revealed MSH2, the human homolog of which was later found to be 
mutated in a hereditary form of colon cancer (Fishel et al., 1993; Strand et al., 1993).  
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     Yeast cells have also been essential for studies of proteins involved in rarer genetic disorders. 
One example of this is Friedreich's ataxia, a neurological disorder caused by a mutation in the 
gene FRDA1. Deletion of the yeast homolog of FRDA1, YFH1, resulted in improper accumulation 
of iron in the mitochondria and disruption of respiration (Babcock et al., 1997; Wilson and Roof, 
1997). This early insight into the function of FRDA1 has driven current research, including 
development of iron chelators as a therapeutic intervention for individuals with Friedreich’s 
ataxia (Becker and Richardson, 2001).  
      Yeast are also useful for modeling diseases in which there either is not a yeast homlog or a 
yeast homolog has yet to be discovered. I have already discussed yeast models of the 
synucleinopathy-related protein α-syn, and yeast models have been developed for proteins 
involved in other neurodegenerative diseases, such as Huntington’s disease, Alzheimer’s 
disease, and amyotrophic lateral sclerosis (Johnson et al., 2009; Krobitsch and Lindquist, 2000; 
Treusch et al., 2011).  Yeast have also been used to heterologously express and study cancer-
related genes, including caspases and p53 (Pereira et al., 2012). Furthermore, a third class of 
genes that have been successfully studied in yeast are those involved in kidney disease (Kolb et 
al., 2011). This includes ion channels, plasma membrane transport proteins, aquaporins, and 
signaling proteins. Many of these proteins are complex, containing multiple membrane 
spanning domains or require interactions with other proteins for their correct folding and 
localization. The fact that these proteins function similarly in yeast as mammalian cells is 
remarkable and highlights the high level of cellular conservation between yeast and higher 
organisms.   
     Finally, one of the biggest advantages of the yeast system is the potential using screens to 
accumulate vast amounts of data including protein-protein interactions, gene expression 
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profiles, and effects of overexpressing or deleting genes. As modeling through systems biology 
becomes more advanced, algorithms are being used to uncover complex biological processes 
employing this data from yeast and discovering ties to human disease (Petranovic and Nielsen, 
2008). These networks can highlight pathways perturbed by expressing heterologous disease-
associated proteins in yeast, as elucidated through unbiased analyses (Yeger-Lotem et al., 
2009).  
     Of course, S. cerevisiae do have some limitations in terms of their suitability for modeling 
complex disease. Processes involving protein interactions with partners that are not fully 
understood and lack yeast homologs are less likely to be easily studied. This may have 
contributed to problems I experienced with modeling dystonia, as discussed below. Other 
pathways, while conserved in yeast, are much simpler than in higher organisms, so studies in 
yeast miss details that may be essential for function. One example of this is the electron 
transport chain in the mitochondria: yeast replace the entirety of complex I (45 subunits in 
mammals) with a single enzyme, Ndi1p (Carroll et al., 2006; De Vries et al., 1992). Furthermore, 
and perhaps more importantly in the context of human disease, as single-celled organisms, 
yeast are not an ideal model for disease processes that rely on cellular contacts or creation of 
full tissues or organs. This becomes especially relevant when considering systems like immune 
function or neuronal communication.  
       However, while yeast sometimes lack processes identical to those involved in human 
disease progression, yeast may have a simpler system that can still provide important insight. α-
Syn is an example of this. Yeast do not display the process of regulated secretion that α-syn is 
thought to play a role in governing: all secretion in yeast is constitutive. However, studying the 
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mechanism by which α-syn hinders constitutive secretion in yeast has provided insight into 
how α-syn affects specialized secretion in the nervous system.  
     In this thesis, I have described two projects, one successfully modeling the splice isoforms of 
α-syn in yeast and the other failing to find a phenotype associated with torsinA expression in 
yeast. Herein I will outline future directions for both of these projects and discuss what they tell 
us about the strengths and limitations of using yeast to model human disease.  
 
Future directions: α-syn splice isoforms 
     Within this thesis, I used yeast to assess the biophysical properties of two splice isoforms of 
α-syn, one lacking exon four (α-synΔ4) and one lacking exon six (α-synΔ6). These splice 
isoforms are differentially expressed in synucleinopathies; however, little is known about their 
biology. My studies revealed differential toxicity and localization of the splice isoforms as 
compared full length α-syn (α-synFL). Using yeast as our model organism enabled such 
thorough investigation of the biological differences between these isoforms. We were able to 
generate strains that we knew expressed the same levels of each isoforms. Such matched strains 
would be much more difficult to construct in higher organisms, highlighting the power of using 
yeast to study heterologous genes.  
     We further utilized yeast in high-thoughput analyses to ask how the splice isoforms 
differentially affect cell biology. Again, these studies would have been technically much more 
challenging, or impossible, in higher organisms. We discovered that expression of the splice 
isoforms differentially sensitize yeast to changes in sterol biology. There is a complicated 
history of the role that sterols play in synucleinopathy progression. Some studies show high 
cholesterol levels to be associated with increased risk of synucleinopathy, while others suggest 
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the opposite (Huang et al., 2008; Muller et al., 1995; Wolozin et al., 2007). We found that cells 
expressing α-synFL and α-synΔ6 are also sensitive to drugs that block sterol synthesis, while 
control cells and cells expressing α-synΔ4 are resistant. Therefore, it is possible that there are 
ties between splice isoforms levels and differential impact of cholesterol on synucleinopathy 
progression, but significant future work is required to fully understand the biology of the splice 
isoforms in this and other contexts.  
     First, more work is necessary to understand the membrane binding properties of the splice 
isoforms. α-SynFL has been shown to bind sterols (Fantini et al., 2011; Fortin et al., 2004) and 
addition of cholesterol promotes α-synFL binding to a vesicle bilayer in vitro (Kamp and Beyer, 
2006). This suggests that α-synΔ4 may be less able to interact with membrane sterols; 
consequently, it would be interesting to investigate the in vitro lipid binding properties of this 
splice isoform.  
     Some studies of this type are already underway. Single-molecule fluorescence resonance 
energy transfer (FRET) studies revealed that α-synFL folds differently in the presence of varying 
concentrations of the lipid mimic SDS, depending on whether SDS is in a flat membrane 
conformation versus a spherical micelle (Ferreon et al., 2009). Through collaboration, the Deniz 
lab is currently investigating the ability of the splice isoforms to assume these various 
conformations in similar ways and will hopefully be able to extend these studies to examining 
the affect of adding cholesterol to these membranes. This approach, combined with assays to 
investigate the ability of the splice isoforms to interact with different membranes would provide 
a more complete picture of the lipid binding properties of the α-syn splice isoforms.  
     While we highlight intracellular localization differences between the α-syn splice isoforms in 
yeast, this should be extended to tissue culture cells. There are two options for pursuing this. 
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First, it has been found that transgenic mice modestly overexpressing α-synFL-GFP show that it 
localizes to synaptic boutons in hippocampal neurons (Scott and Roy, 2012; Scott et al., 2010). 
While it is time consuming and expensive to make transgenic mice, mice expressing α-synΔ4-
GFP and α-synΔ6-GFP would be very informative to examining the localization of the splice 
isoforms. A second option focuses more on the membrane binding properties of the splice 
isoforms, although it utilizes HeLa cells instead of neuronal cells. Previous work found that it is 
possible to visualize the membrane binding properties of α-syn by using digitonin to 
permeabilize HeLa cells transfected with α-syn (Fortin et al., 2004). This led to a loss of 
cytoplasmic α-syn and revealed that the remaining α-syn localized to lipid rafts, which are 
regions of the membrane concentrated in specific proteins and lipids such as cholesterol. This 
suggests that α-syn may associates more tightly with this area of the membrane. Membrane 
binding to lipid rafts was lost by the disease-associated variant α-synA30P, which has been 
extensively shown to be unable to bind lipids. It would be interesting to repeat this experiment 
with cells expressing α-synΔ4 and α-synΔ6, and upon altering cellular sterol content, in attempt 
to recapitulate my yeast results.  
     In this thesis, I also showed that α-synΔ4-expressing yeast cells are less sensitive to sterol 
inhibition than α-synFL- or α-synΔ6-expressing yeast. Extending these studies to neuronal 
culture has proven challenging. I attempted to investigate whether rat primary neuronal cells 
expressing α-syn splice isoforms also showed differential sensitivities to statins. This was 
difficult due to the extreme sensitivity of these cells to even small concentrations of the drugs. 
One option would be to work with other cell types that may be less sensitive to statins; 
however, using cells other than neurons may be less relevant to disease and α-syn 
overexpression is not toxic to all types of mammalian cells, complicating these analyses.  
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     Another avenue for future research is the mechanism by which OSH proteins differentially 
regulate α-syn-induced toxicity. Here, I showed that OSH2 and OSH3 enhance α-synΔ4- and α-
synΔ6-induced toxicity, while they suppress the toxicity elicited by α-synFL. Little is known 
regarding the mechanism of action of OSH2 and OSH3, but a recent paper demonstrated that 
OSH3 localizes to endoplasmic reticulum (ER)-plasma membrane contact sites and regulates 
local phosphatidylinositol 4-phosphate levels at these sites (Stefan et al., 2011). Given the 
localization of α-syn to the plasma membrane and its impact on secretory vesicles originating 
from the ER, it will be important to determine if α-syn localizes to these same contact sites. In 
work not reported here, I also found that the other OSH family members have no impact on 
toxicity induced by any of the α-syn isoforms. This potentially provides insight into important 
differences between the functionality of OSH family members. 
     Finally, there were other genes that, when overexpressed, differentially modified the splice 
isoforms as compared to α-synFL. Most only produced small differences, but the most notable 
unexplored difference was that PHO80 suppressed toxicity of α-synFL and α-synΔ4 and 
enhanced α-synΔ6 (data not shown). PHO80 is a cyclin that has been linked to nutrient sensing, 
as well as some pathways previously associated with α-syn-induced toxicity, such as calcium 
homeostasis and metal accumulation.  This suggests that the α-synΔ6 may differentially affect 
these processes, which should be studied further. Also, given that α-synΔ6 lacks a portion of the 
C-terminal tail of the protein important for protein-protein interactions, it could serve as a 
useful tool for studying potential interacting partners of α-synΔ6 to α-synFL.  
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Future directions: torsinA 
     Here, I also outlined my attempts to use yeast to study the dystonia-related protein torsinA. It 
has previously been shown that torsinA regulates ER stress (Chen et al., 2010). Given the high 
level of conservation in ER stress pathways and genes between yeast and higher organisms, I 
hypothesized that I may be able to recapitulate torsinA’s role regulating ER stress in yeast, even 
though yeast lack an endogenous torsinA homolog. Unfortunately, in contrast to the situation 
encountered upon heterologous expression of α-syn in yeast, I was unable to uncover any 
stress-related phenotypes associated with torsinA expression in yeast. However, this early work 
can serve as a platform for future torsinA studies. As cofactors of torsinA are discovered, our 
model can be utilized to test if these modifiers are necessary for torsinA to function in yeast. 
There is still many unknowns concerning the role of torsinA in ER stress and I am optimistic 
that future work will uncover details necessary for modeling torsinA biology in yeast.  
     In the time since I have ceased attempting to model the consequences of torsinA in yeast, 
some advances have been made in this field that may provide new insight into modeling this 
protein's cellular function. TorsinA was found to act in endoplasmic reticulum associated 
degradation (ERAD) (Nery et al., 2011). These authors also found that ERAD was inhibited by 
overexpression of the disease-associated mutant form of torsinA as well as downregulation of 
wild type torsinA. If there was a defect in ERAD upon overexpression of mutant torsinA in my 
studies, the unfolded protein response reporter I used in these studies would have detected it, 
but is relevant to consider in designing future studies.  
     Yeast two-hybrid analysis of a torsinA isoform lacking the first forty amino acids yielded an 
interaction partner, Printor, which was also shown to physically interact with torsinA in higher 
organisms (Giles et al., 2009). Notably, full-length torsinA failed to produce any positive hits in 
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this same screen. These first forty amino acids encode the signal sequence and a hydrophobic 
domain. The authors reasoned that removal of this domain might simply interfere with the 
ability of the protein to translocate into the nucleus, which would be essential for the assay. 
However, this modification could also be interfering with other critical aspects of torsinA 
function when expressed in yeast. I performed some preliminary studies with torsinA lacking 
the first 40 amino acids but all of my results still suggested that this form of torsinA was not 
active in my assays. Any future work on this topic should consider these results carefully. It is 
possible that modification or removal of other domains may allow more fruitful studies, 
although the biological significance of such modifications could temper enthusiasm of any 
positive results obtained.  
     Another possible problem with modeling torsinA in yeast stems from the fact that yeast lack 
some of the known binding partners of torsinA, such as LULL1 and LAP1 (Goodchild and Dauer, 
2005). While these proteins are thought to be more important for the ability of torsinA to target 
the nuclear envelope than for its activity in the ER, it is possible that torsinA requires these 
interactions for its role in regulating ER stress. Ectopic coexpression of these proteins with 
torsinA in yeast may help to create a functional dystonia model. Future work in higher 
organisms, especially efforts to define other accessory proteins necessary for torsinA function, 
may provide insights that will allow successful creation of this yeast model. 
     I was fortunate to be able to publish our unsuccessful attempts to model TorsinA in yeast, due 
to the extremely rigorous way in which I attacked this problem. However, these types of 
publications are rarely seen in the literature. This is a shame. Examination of unsuccessful 
experiments can be extremely helpful. They provide important insights that allow scientists to 
more carefully craft future experimental efforts. Furthermore, they prevent other labs from 
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duplicating the same studies and wasting valuable time and financial resources. Gone are the 
days where one must scour paper journals in a library to find articles of interest. We live in an 
age where a simple internet search will quickly reveal any publication on any topic. With the 
rise of internet-based journals, which do not have the same limitations imposed by publishing 
costs and are able to focus on judging science more for its thoroughness and quality of 
investigation, there is an obvious forum for these types of results. Hopefully, this will prompt 
more scientists to craft these types of publications and expand the scientific dialogue to include 
both positive and negative results, when they are properly and rigorously controlled. 
 
Future directions: modeling human disease proteins in yeast  
     Looking to the future, what can we learn from successes and failures of studying human 
disease proteins in yeast that will allow us to better select novel proteins to attempt to model? 
First, it is important to strongly consider what is already known about the protein of interest. 
The success of the yeast models expressing proteins involved in neurodegenerative diseases is 
tightly linked to their function. They are all small proteins or peptides that cause cellular 
dysfunction by interrupting highly conserved processes. In the case of α-syn, its primary 
binding partner and site of induced toxicity are cellular membranes, a component of every 
eukaryotic cell. Its primary impact is on vesicle secretion, an extremely conserved process. 
These factors contribute into the ability of α-syn dysfunction to be effectively modeled in yeast. 
Other neurodegenerative disease proteins that have been successfully modeled in yeast are 
similar. For example, Aβ, a peptide associated with Alzheimer’s disease, induces toxicity upon 
expression in yeast and affects similar processes to those in higher organisms (Treusch et al., 
2011). Again, Aβ is a small peptide that is inherently prone to aggregation, affecting highly 
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conserved processes like endocytosis. Importantly, however, these proteins are not simply 
causing toxicity by aggregating and blocking up protein turnover systems. Each protein triggers 
a unique signature of phenotypes in yeast, many of which have been found to be relevant to 
their corresponding disease.  
     While torsinA regulates conserved cellular processes, it also is a complex protein with 
multiple domains and many non-conserved binding partners. These factors probably limited 
my success in modeling torsinA biology in yeast. However, while these types of proteins may be 
more complicated to model in yeast, this should not be viewed as a complete deterrent. As 
noted above, there has been much success in modeling transporters involved in renal function 
in yeast. These proteins are complex transmembrane proteins that one might assume would be 
hard to express heterologously. The fact that yeast have proteins that function similarly, while 
not direct homologs, may provide one clue to the reason for the success of these studies. 
Therefore, even if there are doubts concerning the ability to create a yeast-based model for 
certain proteins, the results may be surprisingly fruitful, as long as experiments are designed 
rationally, keeping in mind the limitations of the yeast system. 
 
Concluding remarks 
     While yeast have been used as a model system for decades, there has been a recent explosion 
in using them to model disease via expression of heterologous proteins, especially proteins 
involved in neurodegenerative diseases. This is likely because yeast  are a simple system with 
an already developed set of powerful assays, yet share significant cellular conservation with 
higher eukaryotes. While some disease-related proteins are more difficult to model in yeast 
than others, the scientific advances that can derive from an effective yeast model often outweigh 
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the risk that the protein may not function in yeast. Hopefully more labs will undertake this 
challenge, resulting in more yeast-based models of human disease-related proteins as well as 
the accompanying scientific advances that yeast models can yield, which can truly advance our 
treatment using human disease.  
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Using Split-GFP to Study the Self-
Interaction of α-Synuclein 
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Abstract 
     Split-GFP has been widely used as a method to determine if two proteins are able to 
physically interact within the context of a living cell. Previous split-GFP studies have already 
shown that α-syn-α-syn self-interactions occur in tissue culture cells. We extended this study to 
examine these interactions in the yeast Saccharomyces cerevisiae, with the goal of enabling a 
screen for factors that either increase or decrease α-syn-α-syn self-interaction. While we were 
able to create a system that was bright enough for us to visualize these interactions using low-
throughput fluorescent microscopy, the signal was too dim to be used in high-throughput 
applications. This limited the utility of our model for making broad observations about the 
localization of α-syn-α-syn interactions in the yeast cell.  
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Introduction  
     α-Synuclein (α-syn) is a small lipophilic protein associated with a number of 
neurodegenerative disorders, collectively termed synucleinopathies, the most prevalent of 
which is Parkinson’s disease. Mutations in and genomic multiplications of the gene encoding α-
syn are associated with early-onset forms of these diseases. Furthermore, the protein itself is a 
principle component of Lewy bodies, intracellular aggregates that form in the surviving neurons 
of patients with certain synucleinopathies (Dauer and Przedborski, 2003). While large protein 
aggregates are prominent in brain slices, many believe it is actually smaller-order oligomers 
that drive disease progression (Conway et al., 2000). 
     The earliest papers published on α-syn expression in yeast showed that the protein was able 
to localize to the plasma membrane, as well as both small peripheral and large intracellular foci 
(Outeiro and Lindquist, 2003).  It was later found that these foci represent clumps of secretory 
vesicles, which are decorated with α-syn (Gitler et al., 2008). These vesicles accumulate because 
α-syn inhibits the ability of vesicles formed in the endoplasmic reticulum (ER) to fuse with the 
Golgi apparatus.  
     Previous efforts in our lab to uncover higher-order protein species of α-syn upon expression 
in yeast have had variable results (unpublished observations). Since α-syn expression in yeast 
does elicit toxicity, this toxicity in the absence of higher-order aggregates fits with the model 
that dynamic oligomers, which would be harder to extract, are the toxic species as opposed to 
stable amyloid aggregates. It is unclear if this is due to the technical constraints of studying 
protein-protein interactions following protein extraction or if the cellular environment of S. 
cerevisiae inhibits α-syn self-interactions. To answer this, we developed a method using split-
GFP to look at α-syn-α-syn self-interactions in vivo. 
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     The split-GFP method utilizes the fact that GFP can be split into two halves, each of which is 
non-fluorescent on its own. However, when brought physically close enough together, the two 
halves are able to assemble into a functional fluorescent molecule. When these two halves of 
GFP are used to tag proteins, it is assumed that complementation will only occur to a significant 
degree if the two tagged proteins directly interact (Hu et al., 2002). This was successfully used 
to study α-syn interactions in cultured mammalian cells (Outeiro et al., 2008); however, in this 
study, complemented split-GFP fluorescence could be seen throughout the cell with no specific 
intracellular localization discernible. Here, we utilized this same method to examine if α-syn 
self-interactions occur in S. cerevisiae.  
 
Results 
Expressing α-syn tagged with split-GFP 
     Throughout this study, “splitN” will be used to describe the N-terminal half of GFP and 
“splitC” will be used to describe the C-terminal half. Early attempts at creating constructs to 
express α-syn tagged with each side of split-GFP, as described in (Outeiro et al., 2008), failed due 
to low or no expression of α-syn-splitC. In these constructs, splitN contained amino acids 1-155 
of GFP, while splitC contained amino acids 156-238 of GFP. Therefore, we turned to a split-GFP 
system developed for expression in yeast (Barnard et al., 2008; Barnard and Timson, 2010), in 
which splitN contained amino acids 1-157 of GFP and splitC contained amino acids 158-238 of 
GFP. While multiple combinations of these two sets were tried, we were surprised to find that 
the pair that showed the highest amount of fluorescence was splitN with amino acids 1-155 of 
GFP and splitC with amino acids 158-238 of GFP (Figure A1.1a). A construct was generated that 
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expressed both splitN-α-syn and α-syn-splitC within the same construct, which will be referred 
to as α-syn-splitTotal (Figure A1.1b).     
      Strains were created for α-syn-splitC alone and α-syn-splitTotal that displayed 
approximately the same toxicity. All strains made with splitN-α-syn alone showed no toxicity. A 
Western blot elucidated the reason for this. There was much lower expression of splitN-α-syn 
than α-syn-splitC, even in the α-syn-splitTotal strains that have equal numbers of integrated 
copies (Figure A1.2). This is likely due to instability of the splitN-α-syn, since moving splitN-α-
syn to the site on the plasmid from which α-syn-splitC was being expressed did not increase 
expression of splitN-α-syn (data not shown).We can conclude that splitN-α-syn and α-syn-splitC 
stably interact as evidenced by the higher band that appears in the α-syn-splitTotal sample at a 
slightly higher molecular weight than α-syn-GFP. 
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Figure A1.1. Summary of constructs used.  
(a) Separate α-syn constructs were tagged either C-terminally with the final 81 amino 
acids of GFP or N-terminally with the first 155 amino acids of GFP. These constructs 
are referred to as splitC or splitN, respectively.  
(b) In an attempt to express equal copy numbers of the α-syn-splitC and splitN-α-syn 
constructs, both were subcloned into the same yeast integrating vector. This 
ensured that, while multiple copies of the vector may be inserted, the copy number 
ratio of α-syn-splitC to splitN-α-syn should remain 1:1.  
  
α-syn 
α-syn 
GFP(158-238) 
GFP(1-155) 
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Figure A1.2. Expression of split-GFP constructs.  
Proteins were extracted from cells expressing α-syn tagged with splitC and/or splitN. When α-
syn-splitC and splitN-α-syn are expressed simultaneously, there are lower levels of splitN-α-syn, 
even though both constructs are expressed from the same plasmid. However, evidence that 
splitN and splitC can stably interact is provided by the highest band in the splitTotal 2 lane, 
which is stable even though the samples were boiled for five minutes and run through an SDS-
PAGE gel.  
136 
 
Visualization of α-syn self-interaction 
     When viewed by fluorescent microscopy, α-syn-splitTotal displayed an interesting 
localization pattern. For comparison, a strain of α-syn-GFP that elicits the same level of toxicity 
as the α-syn-splitTotal strain was visualized. As previously shown, α-syn-GFP shows even 
distribution of α-syn around the plasma membrane, small foci at the periphery, and large 
intracellular foci. Although expressed at a high enough level to induce toxicity, the control strain 
containing α-syn-splitC showed no fluorescence (figure A1.3). The other control plasmid splitN-
α-syn could not be expressed at a high enough level to induce toxicity; however, when 
expressed at a level similar to the amount of splitN-α-syn in the α-syn-splitTotal strain, splitN-α-
syn showed no fluorescence. α-syn-splitTotal, however, was fluorescent in a non-contiguous 
pattern around the plasma membrane, suggesting that α-syn-α-syn interactions occur at specific 
locations. Notably, while α-syn-GFP showed fluorescent intracellular foci, α-syn-splitTotal did 
not show any foci.  
     Unfortunately, while specific fluorescent patterns were seen, the signal was very weak. This 
made further analysis of these cells difficult and precluded their use in high-throughput 
applications, as the signal could not be significantly detected from background in flow 
cytometry. Due to this low signal, this project was not continued. 
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Figure A1.3. Visualization of α-syn-α-syn self-interactions.  
Cells were grown in galactose to induce α-syn expression before visualization by fluorescent 
and DIC microscopy. α-Syn-GFP is seen uniformly at the plasma membrane and intracellular 
foci. α-Syn-splitTotal is seen at specific locations at the plasma membrane but not in 
intracellular foci, although α-Syn-splitTotal expressed at a level to induce the same toxicity as α-
syn-GFP. Scale bar = 2μM.  
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Discussion 
     In this study, we examined the α-syn-α-syn self-interactions that occur in yeast using split-
GFP. The N-terminal fragment of GFP was fused to the N-terminus of one α-syn construct while 
the C-terminal fragment of GFP was fused to the C-terminus of another α-syn construct. We 
found that the splitN-α-syn construct was expressed at a significantly lower level, even when 
the same number of genomic copies was integrated. Possibly due to this lower expression of 
splitN-α-syn, the signal achieved in α-syn-splitTotal was quite dim, preventing in-depth study of 
the localization pattern. However, we were still able to make some interesting initial 
observations. 
     One observation was that α-syn-splitTotal showed fluorescence only at specific peripheral 
locations and not in intracellular foci. This occurred even in strains with high levels of toxicity 
that would normally be associated with α-syn foci formation. We present two hypotheses that 
could explain this observation. First, it is possible that when α-syn localizes to foci, it assumes a 
confirmation that prevents α-syn-α-syn self-interactions, even though there is a high local 
concentration of α-syn. Secondly, it is possible that the stabilized α-syn-α-syn self-interaction of 
α-syn-splitTotal (as demonstrated by the fact that these complexes are resistant to denaturing 
by reducing agent and boiling) allows α-syn to be toxic when expressed at a lower level, such 
that these foci are not being formed. Previous studies have found that these foci represent an 
accumulation of secretory vesicles, studded with α-syn and various secretory proteins (Gitler et 
al., 2008). This question could be answered in a number of ways. One option is to perform 
immuno-electron microscopy, looking for the presence of accumulated vesicles with α-syn 
colocalization. Secondly, one could co-express α-syn-splitTotal with α-syn-RFP to look if there is 
accumulation of foci containing α-syn-RFP with or without green signal. However, this method 
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could be confounded by bleed through of the red signal since the signal from α-syn-splitTotal is 
so dim.  
     Furthermore, it was previously shown (Outeiro and Lindquist, 2003), and reproduced here, 
that α-syn-GFP shows uniform localization around the entirety of the plasma membrane, while 
α-syn-splitTotal showed signal at specific points along the membrane. There are many possible 
explanations for what these spots could be, since it is known that the cell periphery is not 
uniform, but instead contains a multitude of different local domains. We would like to offer two 
hypotheses. First, it is known that α-syn causes toxicity by blocking trafficking from the ER to 
the Golgi. Indeed, some of the early aggregates of α-syn that form are accumulations of secretory 
vesicles appearing around the cell surface. This localization pattern is somewhat reminiscent of 
the peripheral ER, and this might be the site of α-syn-α-syn self-interactions. Secondly, many 
studies have shown that α-syn prefers to interact in sterol-rich environments. It is possible that 
the sites of increased α-syn-α-syn self-interaction represent lipid rafts, which are enriched in 
the sterol ergosterol. This question could be answered by looking for colocalization with ER 
proteins or proteins that localize to lipid rafts. However, these colocalization studies would be 
complicated by the low signal level of α-syn-splitTotal. 
     It is likely that one of the reasons that the GFP signal level is so low is due to low levels of the 
splitN-α-syn protein. While it is not known if this low expression is due to instability of the RNA 
or protein, it is unlikely to be due to lower levels of transcription, as expression of the construct 
from the same site on the plasmid as α-syn-splitC did not significantly change expression levels. 
Stability of the RNA could be determined by using real time PCR to compare RNA levels of α-
syn-splitC to splitN-α-syn from plasmids where they are inserted into the same site. This result 
140 
 
could be used to inform educated modifications to the splitN-α-syn construct in an attempt to 
increase the stability of the RNA or protein. 
 
Materials and Methods 
Construction of plasmids 
     GN-link-α-syn was a kind gift from Brad Hyman (Outeiro et al., 2008). For use in the S. 
cerevisiae system, overlap extension PCR was used to attach flanking AatII sites and the Gal 
promoter to GN-link-α-syn. This was then subcloned into the AatII site of pRS304 to make 
pRS304-splitN-α-syn.  
     SplitC (BYP6335) was a kind gift from David Timson (Barnard et al., 2008). Overlap extension 
PCR was used to attach this construct to the C-terminus of α-syn and add SpeI and XhoI sites. 
This was subcloned into 413-Gal (Ronicke et al., 1997). This was then cut with KpnI and SacI to 
isolate the construct from promoter to terminator and subcloned into pRS304 to make pRS304-
α-syn-splitC or pRS304-splitN-α-syn to make pRS304-splitTotal-α-syn.  
Table A1.1. Primers Used. 
# Purpose Sequence 
353 AatIIGal-f GGGACGGACGTCACGGATTAGAAGCCGCCGAGCGGG 
354 Gal-SplitN-f CCCCGGATTCTAGAACTAGTATGGTGAGCAAGGGCGAGGAGCTGTTCACC 
355 Gal-SplitN-r GGTGAACAGCTCCTCGCCCTTGCTCACCATACTAGTTCTAGAATCCGGGG 
356 AatII-α-syn-r GGGACGGACGTCGTCGACTTAGGCTTCAGGTTCGTAGTCTTG 
404 SpeI-α-syn-f GGGGACACTAGTATGGATGTATTCATGAAAGG 
405 α-syn-splitC-f CAAGACTACGAACCTGAAGCCGGAGGATCTGGAGGG 
406 α-syn-splitC-r CCCTCCAGATCCTCCGGCTTCAGGTTCGTAGTCTTG 
446 XhoI-splitC-r GGGACGCTCGAGTTACTTGTACAGCTCG 
  
Yeast strains and growth conditions 
     All experiments were performed in the JK9-3d yeast background. All yeast transformations 
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were completed using the standard lithium acetate transformation protocol (Gietz et al., 1992; 
Gietz et al., 1995). All growth was done at 30°C, with aeration for liquid growth.  
     To induce α-syn expression, cells were grown to log phase in glucose-supplemented minimal 
media [0.67% yeast nitrogen base without amino acids (Fischer Scientific), supplemental amino 
acids (minus those needed as selectable markers) (MP Biomedicals), and 2% sugar]. Cells were 
then diluted in minimal media with raffinose for overnight growth to log phase, at which time 
cells were diluted into minimal media with galactose to be induced for six hours.  
 
Western blot 
     After 6 hours of induction, bead beating was used to lyse cells in lysis buffer (10mM HEPES 
pH7.5, 10 mM NaCl, 1.5 mM MgCl2, 20% glycerol, 0.5 mM phenylmethanesulfonylfluoride 
(PMSF), and 1x protease inhibitor (Roche)). The product was incubated with 0.5% Tween and 
then separated from the beads and cell debris. A BCA assay (Pierce Protein Research) was used 
to quantify protein concentration. Normalized levels of protein were boiled for five minutes in 
NuPage LDS sample buffer (Invitrogen) with reducing agent and run on a 10% Bis-Tris SDS-
PAGE Gel (Invitrogen) and transferred to PDVF membrane. After blocking with 5% milk in PBS, 
the membrane was probed with either mouse anti--syn (BD Biosciences) or rabbit anti-PGK1 
(antibodies-online.com) and a dye-conjugated anti-mouse or anti-rabbit IgG secondary 
antibody (LICOR Biosciences). The blot was visualized using the Odyssey Infrared Imaging 
System (LICOR Biosciences).  
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Microscopy 
     Cells were induced by the method described above. After mounting on a slide, a Nikon Eclipse 
Ti was used to visualize cells by fluorescent microscopy. Z-stacks were taken. After normalizing 
signal over the Z-stack, the images were deconvoluted using the 3D deconvolution algorithm. 
The brightness of the images was adjusted to highlight the localization of the α-syn-split-GFP 
strain, which is significantly dimer than α-syn tagged with GFP.  
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